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Metabolic syndrome is a cluster of disorders, including obesity, atherosclerosis, 
inflammation and insulin resistance. It is associated with increased risk of various types of 
cancers including breast cancer. Obesity in particular is a risk factor for an aggressive 
tumour phenotype and reduced survival of patients with breast cancer. To understand 
the underlying mechanisms I aimed to develop and characterise a metabolic syndrome 
mouse with an orthotopic model of breast cancer.  
 
Apolipoprotein E (ApoE) is involved in the catabolism of triglycerides and cholesterol, and 
the ApoE knockout mouse model is prone to obesity and development of atherosclerosis. 
The double knockout ApoE/ArKO mouse displays all features of metabolic syndrome. At 6 
months of age, wild type, ApoE and ApoE/ArKO C57BL/6 mice were inoculated with the 
murine breast cancer cell line E0771. Growth of tumours in the mammary fat pad and 
mouse weight were measured until tumours reached ethical endpoint. The hypoxia 
marker, pimonidazole, was injected 90min prior to euthanasia, and plasma, organs and 
tumours were harvested and weighed. Half of each tumour was formalin fixed and 
paraffin embedded for Immunohistochemical (IHC) analysis of cancer associated 
adipocytes (perilipin), proliferation (phosphohistone-H3), estrogen receptor status (ERα) 
and hypoxia (pimonidazole adducts). The other half was frozen and processed for tumour 
lysates, which were used to measure hypoxia inducible factor 1 (HIF-1α) by Western 
blotting, and adipokines, using an antibody array. Vascular endothelial growth factor 
(VEGF) and Insulin-like growth factor binding protein 5 (IGFBP5) concentrations were 
further analysed by an ELISA assay. HIF-1α levels in EO771 cells were analysed by 
subjecting the cells to hypoxic conditions. 
 
ApoE mice weighed more than wild type and ApoE/ArKO mice, and showed increased 
cellular proliferation. ApoE/ArKO mice had the least omental fat and the smallest 
tumours. IHC analysis showed that EO771 tumours in ApoE mice had the highest number 
of intratumoral, perilipin positive adipocytes (p<0.01), and tumours from ApoE/ArKO had 




negative for ER-α. Pimonidazole staining was prominent in all tumours, with secondary 
tumours staining strongly. From Western blot analysis, tumours grown in ApoE/ArKO 
mice had the highest level of HIF-1α, and HIF-1α levels were higher in secondary tumours 
compared to primary tumours (p<0.05). A range of adipokines was differentially 
expressed in tumours grown in the three different genetic backgrounds. VEGF 
concentrations were higher in primary tumours from ApoE/ArKO mice than ApoE and 
wild type mice. Primary tumours from ApoE/ArKO mice had significantly lower 
concentrations of IGFBP5 (p<0.01). 
 
My findings show that breast tumours grown in ApoE/ArKO mice have an aggressive 
tumour phenotype, with increased proliferation, tumour hypoxia and VEGF 
concentration. These models represent valuable tools for research that will bridge the 
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Obesity is not only a health crisis in New Zealand but globally. According to the Ministry of 
Health, approximately one third of the female population in New Zealand is obese. This has 
increased by 11% in the past 15 years (1). The World Health Organization (WHO) statistics 
in 2014 state that around 1.5 billion people in the world are overweight, having a body 
mass index (BMI) greater than 25 kg/m2, and 500 million people are considered obese, 
having a BMI greater than 30 kg/m2 (2). 
 
Obesity is one of the components of metabolic syndrome (syndrome X). Metabolic 
syndrome is a group of disorders associated with high plasma lipid levels, inflammation, 
low High Density Lipoproteins (HDL) level, insulin resistance, hyperlipidaemia, high glucose 
level and abdominal obesity (high waist to hip ratio and high BMI >30 kg/m2 );(3).  
 
Breast cancer is the most common cancer among women globally. It is the second largest 
cause of cancer deaths among New Zealand women (4). Female breast cancer patients that 
show signs of metabolic syndrome especially obesity have an aggressive breast tumour 
biology compared to their lean counterparts (4). This results in a poorer response to 
chemotherapy and lower survival rates (4). 
 
Studies have shown that adipocytes adjacent to a breast tumour alter their biology and 
make the tumour more aggressive by increasing proliferation, invasion and metastasis (5). 
Previously, adipocytes were only considered as a source of energy; however, recent studies 
have shown that adipocytes act as endocrine cells secreting hormones, adipokines and 
growth factors (6). These cell-signalling molecules interact with tumour cells and increase 
tumour growth and invasive capacity (7, 8). The interactions of adipocytes with tumour 
cells alter their phenotype to cancer-associated cells (CAA); (7, 8). These CAA provide 
energy to tumour cells thus increasing their growth and invasive capacity (7, 8). CAA also 
cause epithelial to mesenchymal transition (EMT), leading to metastases of breast tumour 





The aim of this project is to understand the relationship between obesity and other factors 
of metabolic syndrome and breast tumour growth. The main focus is understanding how 
cell signalling molecules especially adipokines, secreted from adipocytes adjacent to a 
breast tumour alter tumour biology, and how various animal models have been used to 
understand this association by characterising breast tumour morphology. 
1.1 Metabolic Syndrome 
Metabolic syndrome is a cluster of disorders (Figure 1), which promotes cancer (breast, 
pancreatic, colorectal, endometrium, prostate and hepatocellular cancer), atherosclerosis, 
hypertension and type 2 diabetes (10). These cascades of signals cause an aggressive 




Figure 1: A schematic overview of the metabolic syndrome disorders that promote breast 




1.1.1 Metabolic Syndrome and Breast Cancer 
1.1.1.1 Obesity as a Risk Factor 
Obesity is a disorder that causes inflammation and increases visceral adipose tissue (3). An 
increased risk of postmenopausal and to some extent premenopausal breast cancer has 
been linked to abdominal obesity. 
 
Estrogen receptor positive (ER+) breast cancer is the most common type and accounts for 
nearly 80% of the total cases (12). ER+ breast tumours grow in response to estrogen 
hormone and have a significant amount of estrogen receptors within the breast tumour 
(12). The other form of hormone responsive breast tumour is progesterone receptor 
positive (PR+). PR positive tumours grow in response to the progesterone hormone, which 
is involved in the mensuration cycle and embryogenesis (12). PR+ tumours have a 
significant amount of progesterone receptor within the tumour. Both ER and PR positive 
breast tumours respond to hormone therapy as opposed to ER and PR negative breast 
tumours (12). 
 
The remaining 20% of breast cancer cases are associated with expression of Human 
Epidermal Growth Factor Receptor 2 positive  (Her 2+); (12). These tumours have an 
increased expression of the HER 2 protein. HER 2 protein is involved in signal transduction, 
cell proliferation and opposes cell apoptosis (12). Expression of HER2 needs to be tightly 
regulated as overexpression leads to uncontrolled cell growth (12). HER 2+ breast cancers 
are very aggressive and proliferate rapidly compared to ER+ and PR+ breast cancers (12). 
The other form of breast cancer that is more prevalent in premenopausal women than 
postmenopausal women is the triple negative breast cancer. Triple negative breast cancer 
has a basal-like a phenotype that is ER-, PR- and HER- and is very aggressive (13).  
 
There is a greater risk for obese postmenopausal women of developing ER+ and PR+ breast 
cancer but there is no evidence for ER+/PR – or ER-/PR- (14).  In contrast, obese 
premenopausal women are more likely to develop ER-/PR-/HER- breast cancer but not 
receptor HER 2+ (14). Various studies have reported the role of obesity and breast cancer 





Table 1: A list of recent analysis of case studies over the past ten years showing the association 
of metabolic syndrome and risk of breast cancer 
Source Study and sample  
population 
Risk factors  
Positive association 





et al. (4) 
Case control study 
of 88 patients 
Abdominal obesity, high 
blood pressure, blood 
glucose and plasma lipids 
------------ High blood glucose was 
mainly associated with 
breast cancer risk 
Osaki et 
al. (15) 
Statistical study of 
15386 patients 
All signs of metabolic 
syndrome 






2 case control 
population study 
Hypertension, obesity and 
hyperlipidemia 
------------ Positive correlation 
between metabolic 




Case study of 163 
patients 
Low HDL and high 
triglyceride levels 
------------ Main risk factors for 
breast cancer were low 
HDL and high 
triglycerides. Other 
factors had little impact 
in breast cancer risk 
Jorge et 
al. (18) 
Case study of 
290,00 women 
All signs of metabolic 
syndrome 




et al. (19) 
Case study of 777 
women 
All signs of metabolic 
syndrome 
------------ Multiple risk factors are 
associated with 
postmenopausal breast 
cancer risk as opposed to 
a single factor 
Healy et 
al. (20) 






------------ Later stages of breast 
cancer (ii-iv) at diagnosis 
and increase tumour size 
Kabat et 
al. (21) 
Case study of 165 
postmenopausal 
women 
High glucose, triglycerides 
and blood pressure levels 
------------ Metabolic syndrome 




Cohort study of 176 
patients 
High blood glucose, high 





Triple negative breast 
cancer risk was 




Study of 162 
patients  (81 breast 
cancer patients) 
Obesity ------------ Metabolic syndrome as 
an independent risk 
factor for breast cancer  
Ronco et 
al.  (24) 
Case study of 912 
women (367 breast 
cancer patients) 





Obesity and diabetes 




Population study of 
18,176 middle aged 
women 
------------------------------- Obesity Little impact of metabolic 
syndrome especially 




823 cancer patients Obesity and low HDL levels ------------ Metabolic syndrome 
increase breast cancer 





Studies by (15, 17, 25, 26) show that obesity is a risk factor in postmenopausal women. 
Obese women have a larger tumour size compared to lean women and tend to have later 
stages of breast cancer (stage ii-iv) at diagnosis (20). On the other hand, Inoue et al. and 
Maiti et al. (22, 25) found that obesity did not affect tumour growth in postmenopausal 
women and found no correlation between BMI and breast cancer, and breast cancer is 
independent of BMI status. 
 
Despite the conflict in the literature, more studies have shown that there is a positive 
association between obesity and breast cancer and obesity is a major risk factor in breast 
tumour growth and progression. Capasso et al. (19) found that obesity alone cannot lead to 
breast tumour development and has to be coupled with other factors of metabolic 
syndrome to show the positive association. Most case studies have reported that 
postmenopausal women who are obese show at least two other disorders of metabolic 
syndrome (Table 1). It has been reported that obesity acts as an independent risk factor for 
breast cancer recurrence after initial diagnosis and causes distant metastasis due to poor 
response to adjuvant chemotherapy (27). However, this is not observed in patients 
diagnosed with breast cancer with BMI less than 25 kg/m2 (27). 
1.1.1.2 Triglyceride as a Risk factor 
Atherosclerosis is a chronic inflammatory disease promoted by metabolic syndrome as a 
result of increased plasma triglyceride levels and cholesterol levels (28). Atherosclerosis  
causes formation of plagues in arteries that cause heart attacks, peripheral vascular disease 
and stroke (28). Increased triglyceride levels have been associated with an increase in risk 
of both atherosclerosis and breast cancer especially among the postmenopausal women (4, 
16, 22). 
1.1.1.3 Other Disorders of Metabolic Syndrome as a Risk factor 
Not only obesity, but high cholesterol levels, insulin resistance and hypertension have been 
shown to be associated with increased breast tumour growth (Table 1). Low HDL and high 
LDL cholesterol levels have been shown to increase breast cancer risk in postmenopausal 
women (17, 22, 26). This is because cholesterol is a precursor molecule in the biosynthesis 








Figure 2: Biosynthesis pathway of estrogen from cholesterol 
The diagram shows the biosynthesis pathway of estrogen from cholesterol. It shows the potential 
genes encoding the enzymes involved in estrogen biosynthesis (CYP17, CYP19 and 17-HSD) and 





Low levels of HDL are an indicator of excess estrogen production, which has also been 
shown to increase the breast cancer risk in postmenopausal women (29). Few studies have 
shown that hypertension also increases the risk of breast cancer in postmenopausal 
women (16, 21). However, in one case study, obesity did not affect breast tumour growth 
in triple negative breast cancer patients (22). The mechanism of association between 
breast cancer and hypertension is not well understood, however inflammation is thought 
to be the linking factor (31). 
 
Increased glucose and insulin resistance also plays a major role in increasing breast cancer 
risk among postmenopausal women but not in premenopausal women. In premenpausal 
women it has a protective effect against breast cancer progression (4, 18, 20-22, 24). 
Insulin resistance positively correlates with the production of adipokines and pro-
inflammatory cytokines from adipocytes (32). Overexpression of adipokines and cytokines 
increases breast cancer risk (32). Metabolic syndrome not only increases breast cancer risk 
but has also been shown to increase the risk of cardiovascular diseases, atherosclerosis and 
type 2 diabetes mellitus (4, 31). 
1.2 Breast Tumour Microenvironment 
The breast tumour microenvironment consists of a dynamic composition of stromal cells 
and cancer cells (33); (Figure 3). The stromal component comprises adipocytes, cancer 
associated fibroblasts (CAFs), tumour associated macrophages (TAMs), endothelial cells 
and immune cells (33). The stromal cells release cell-signalling molecules such as 
adipokines and pro-inflammatory cytokines that cross talk with tumour cells and promote 
their proliferation, invasion and metastases (33). On the other hand tumour cells secrete 




















Figure 3: A schematic representation of stromal cells in a dynamic breast tumour 
microenvironment 
Breast tumour growth, invasion, metastasis, angiogenesis, drug resistance and immune 
suppression are a result of the following factors: Leptin, adiponectin, aromatase, IL-6 (interleukin 
6), COLVI (collagen VI), VEGF (vascular endothelial growth factor), TNF- (tumour necrosis factor 
alpha), MMP (metalloproteinase), EGF (epithelial growth factor), HGF (hepatocyte growth factor), 
PGE2 (prostaglandin E2), TGF- (transforming growth factor beta) and RANKL (Receptor activator 
of nuclear factor kappa-B ligand (33). 
 
 
1.2.1 Cancer Associated Fibroblasts, Tumour Associated Macrophages, Immune 
Cells and Endothelial Cells in Breast Tumour Microenvironment 
Macrophages are produced by differentiation of monocytes and express CD34+ proteins 
(34). They circulate in the blood stream as pro monocytes and extravasate into tissue and 
differentiate into specific tissue macrophages (34). Macrophages are one of the major 
populations of tumour infiltrating immune cells. Cytotoxicity of macrophages during early 
stage immune response inversely affects prognosis by enhancing cancer progression (35). 
The local macrophages in tumour microenvironment exhibiting pro-tumour activity and are 
referred to as TAMs (35). TAMs, a M2 phenotype, secrete growth factors that promote 
angiogenesis, invasion, migration, proliferation, metastasis, matrix relocation and 




cells potentially causes immunosuppression. This supresses the anti-tumour activity of 
macrophages by secretion of PGE2 and IL-10 (34). PGE2 are lipid mediators’ synthesised by 
cyclooxygenases that are involved in inflammatory response (37). It has been reported that 
PGE2 contributes to acute inflammation that potentially initiates tumour activity (38, 39). 
 
Other immune cells along with macrophages also promote breast tumour growth and 
invasion.  Excessive infiltration of immune cells, especially lymphocytes, in the breast 
tumour stimulates secretion of RANKL from CD4+CD25+ (40). RANKL is a member of the TNF 
family and promotes tumour progression and distant metastases by inducing angiogenesis 
mediated by inflammation(41).  
 
Endothelial cells, a semi selective barrier, are also involved in breast cancer growth and 
invasion beside their role in vascularisation (42). TNF- production by endothelial stromal 
cells forms a cascade of signals that lead to over expression of CXCL1/2 that promotes 
tumour cell survival and increases chemo resistance (42). 
 
Fibroblasts are part of the extracellular matrix (ECM); (43). The local tumour cells secrete 
chemokines that activate fibroblast phenotype to cancer associated fibroblasts (CAFs) (43). 
CAFs play an important role in breast cancer progression and invasion (33). They secrete 
various growth factors including TGF-, VEGF, HGF and matrix metalloproteinases (33). Of 
these secretory factors TGF- is the key player involved in EMT (44).  EMT leads to loss of 
function of the endothelial cells and increases cancer cell motility (44). CAFs not only 
promote breast cancer progression and invasion but also cause metastasis of the tumour 
to secondary organs (44).  
1.2.2 Adipocytes in Tumour Microenvironment 
Adipocytes are the most abundant cells surrounding breast tumour cells, and are involved 
in paracrine, endocrine and autocrine signalling (45). Previously adipocytes were only 
considered as an energy source; however, recent studies have shown that they act as 
endocrine cells (6). They secrete cell-signalling molecules such as hormones, adipokines 
and pro-inflammatory cytokines (6). These cell-signalling molecules are involved with 
tumour proliferation, invasion and motility (5). A crosstalk between adipocytes and tumour 




1.2.2.1 Cancer Associated Adipocytes  
CAAs have an altered phenotype from normal adipocytes with decreased size with less lipid 
accumulation and overexpression of cytokines (IL-6) and proteases (MMP-11); (7-9); 
(Figure 4). Cancer cells co-cultured with CAA showed increased radio resistance and 
decreased cell death compared to tumour cells alone (7). This association causes aggressive 
tumour biology by increasing the invasive capacity of the breast tumour cell, and CAA 
shares inflammation as a common trait with obesity by overexpression of IL-6 and under 
expression TNF - (8). One of the first studies done by Sullivan et al. (46) showed secretion 
of IL-6 by CAA induces EMT by increasing the repulsive force of E-Catherin causing distant 
metastases of breast tumour cells to secondary organs (46).  
 
 
Figure 4: Cross talk between breast tumour cells and adipocytes forming cancer associated 
adipocytes. 
Recruitment of cancer cells adjacent to adipocytes forms Cancer Associated Adipocytes (CAA). 
CAA provides Free Fatty Acids (FFA) and other nutrients for survival of cancer cells. CAA also 
release cytokines; interleukin 6 and 8 (IL-6 and IL-8) that increases tumour proliferation, invasion 
and metastasis (5). 
 
1.2.3 Tumour Microenvironment and Hypoxia 
The breast tumour microenvironment plays an important role in initiating tumour hypoxia. 
The stromal components aid tumour hypoxia by increasing tumour proliferation limiting 
oxygen supply. At low oxygen concentrations, the hypoxia inducible factor 1 (HIF-1) is 
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activated (47). HIF-1 is a heterodimer comprising of oxygen sensitive alpha and a 
constitutively expressed beta subunit (47). Over 500 genes that are involved in energy 
metabolism, hormone regulation, growth, angiogenesis, invasion and metastases are 
regulated by the HIF-1 (Figure 5); (47).  
 
 
Figure 5: HIF-1 target genes during tumour development 
The figure above represents the genes that are directly transcribed by HIF-1 that are involved in 
tumour metabolism, growth, angiogenesis, invasion and metastases (47). 
 
Tumour development depends on increased metabolism and an adequate blood supply. 
HIF-1 regulates genes involved in glycolysis as well as glucose transporter that support 
tumour metabolism and survival (48). Since hypoxia is a major inducer of angiogenesis, 
VEGF is frequently overexpressed within the tumour (49). VEGF is a signalling protein that 
increases vascularization (angiogenesis) that restores oxygen supply in the tumour due to 
inadequate blood supply (50). It has been reported that VEGF is associated with tumour 
invasion and distant metastases (51). HIF-1 is also involved in tumour invasion and 
metastases by down regulating E-cadherin expression, which is a major indicator of EMT 
(52). 
 
FIGURE 1 | Direct transcriptional targets of HIF.
FROM THE FOLLOWING ARTICLE:
Oxygen sensing by HIF hydroxylases
Christopher J. Schofield & Peter J. Ratcliffe
Nature Reviews Molecular Cell Biology 5, 343-354 (May 2004)
doi:10.1038/nrm1366
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The figure shows the protein products of the genes for which there is
evidence of direct transcriptional activation by hypoxia-inducible factor
(HIF). For a fully referenced version of this figure, see online




1.3 Role of Different Factors of Adipose Tissue in Breast Tumour 
Progression 
1.3.1 Hormones and Growth Factors 
Obesity results in over expression of insulin like growth factors (IGFs) and increased 
production of estrogen due to overexpression of aromatase (53). This results in an 
increased incidence of ER+ breast cancer (54). IGFs cross talk with macrophages and 
increase their migration and invasive capacity (55). IGFs also trigger macrophages to 
secrete pro inflammatory cytokines resulting in increased breast tumour growth (34). 
 
Aromatase is an enzyme that is involved in the conversion of androgens to estrogen. It is 
encoded by the CPY 19 gene and is a member of the cytochrome P450 family (56). In 
premenopausal women the ovarian follicle mainly produces aromatase. On the other hand 
aromatase in postmenopausal women is produced in adipose tissue and skin (56). Obese 
postmenopausal women have increased levels of aromatase, which elevates estrogen 
levels (56). Increased estrogen levels in post menopausal women is associated with 
increased risk of breast cancer (56). Moreover obesity being a chronic inflammatory 
disorder increases the secretion of pro-inflammatory cytokines such as TNF- and IL-6 (56).  
1.3.2 Pro-inflammatory Cytokines 
Inflammation triggered by obesity in subcutaneous and visceral adipose tissue increases 
breast cancer risk by the secretion of pro-inflammatory cytokines such as tumour TNF -, 
cyclo-oxygenase-2 (Cox-2), IL-1 and IL-6 (54). The secretion of these pro-inflammatory 
cytokines increases aromatase expression and activity, and TNF- regulates the expression 
of aromatase and IL-6, and overexpression of these promotes breast cancer invasion and 
migration (54). In vivo studies have shown COL VI to promote early stage tumour growth 
and metastasis (57). 
1.3.3 Adipokines 
Adipokines are small peptide hormones secreted from adipocytes. They alter breast 
tumour biology by increasing breast tumour cell proliferation, invasion and metastases 
(58). The main types of adipokines associated with breast tumour development are leptin 
and adiponectin. Other adipokines associated with breast tumour progression are resistin, 





Leptin is a small peptide hormone discovered in 1994 that is encoded by the obese (ob) 
genes and binds to the ob receptor (61). Leptin plays a major role in energy homeostasis. 
Adipocytes are the main sites of leptin secretion; however, malignant breast tissue has also 
been found to be a site of leptin secretion(62). 
 
Leptin levels in serum are directly proportional to BMI status, and leptin levels are higher in 
obese patients compared to their lean counterparts (63, 64). The association of leptin in 
breast cancer development is also dependent on the menopausal status of women(63). 
Studies of human sample show that overexpression of leptin increases the breast cancer 
risk in postmenopausal women but not premenopausal women (63).   
 
In vitro data show that leptin stimulates proliferation of MCF-7, an ER+ breast cancer cell 
line, T47-D, a PR+ breast cancer cell line, and MDA-MB-231, an ER- breast cancer cell line 
(65-67). Leptin stimulates proliferation of MCF-7 cells by inhibiting P53 or caspase 9 action 
(68-72). On the contrary Ray et al. (73) shows that leptin has anti-proliferating activity in 
MCF-7 cell line due to overexpression of COX 2 as it supresses proliferation. In the MDA-
MB-231 cell line, leptin triggers proliferation by activating the STAT3 pathway, and when 
levels of cAMP decrease leptin suppresses apoptosis (73, 74); (Figure 6). Leptin has also 
been shown to elevate aromatase expression that results in up regulation of ER (75). 






Figure 6: Adiponectin, leptin and estrogen signalling pathway in obesity related breast tumour 
progression. 
Low levels of adiponectin activate the MAPK (mitogen activated protein kinase), AMPK (AMP 
activated protein kinase and Cyclin D1 not shown in this diagram. Estrogen activates aromatase 
expression inducing breast carcinogenesis. Leptin activates both the estrogen and STAT3/JAK2 
(signal transducer and activator transcription 3 / Janus kinase 2). Leptin also activates caspase 9, 
MAPK and PI3K (phosphoinositide 3 kinase) not shown in this diagram (58, 61). 
 
In vivo experiments using MMTV-TGF-α mice deficient in leptin (Lep-/-) found they did not 
develop any breast tumour (76). However, homozygous (Lep +/+) and heterozygous (Lep 
+/-) mice developed mammary tumours (76). Tumour analysis of MCF-7 xenograft nude 
mice treated with leptin shows increased proliferation of breast cancer cells by activation 
of STAT and MAPK pathways (77); (Figure 6). In another study MCF-7 xenograft nude mice 
showed decreased tumour growth by inhibiting the leptin signalling pathway as shown in 
Figure 6 (78). Overall leptin is involved in breast tumour development and proliferation in 
human, in vitro and in vivo studies. 
1.3.3.2 Adiponectin 
Adiponectin is a protein hormone secreted by adipocytes and involved in glucose 
homeostasis and fatty acid oxidation (79). Adiponectin levels are inversely proportional to 
BMI status (79). Obese women have low levels of serum adiponectin compared to lean 
women.  Adiponectin acts as a tumour suppressor and low levels of adiponectin are 




Decreased adiponectin levels have been associated with increased breast cancer risk in 
both premenopausal and postmenopausal women (64, 80, 81). Some studies have 
conflicting data and suggest that increased adiponectin levels only increase breast cancer 
risk in postmenopausal women (82). This is because adiponectin levels are inversely 
proportional to estrogen levels and hence reducing the risk of breast cancer in 
premenopausal women (82). 
 
In vitro studies show that adiponectin resulted in reduced proliferation of MCF-7, T47-D, 
SKBR3, a Her2/neu gene overexpressing breast cancer cell, and MDA-MD-231 cancer cell 
lines (83-88). In contrast two studies showed no anti-proliferative effect of adiponectin in 
MCF-7 and MDA-MD-231 cell lines (83, 89). The anti-proliferative activity of adiponectin is 
mediated by the inhibition of the MAPK, AMPK and Cyclin D1 pathways (84).   
 
In vivo experiments showed similar results as in vitro studies. Nude mice overexpressing 
adiponectin and inoculated with MDA-MD-231 cancer cells had a decreased tumour 
growth rate and size compared to mice with no supplementary adiponectin (90). Human 
association studies along with in vitro and in vivo studies show that adiponectin has anti-
proliferative activity both against ER+ and ER- cell lines. 
1.4  Animal Models in Obesity Related Breast Cancer Research 
Animal models are great tool in research as they bridge the gap between in vitro studies 
using co culture systems and studies involved with human breast cancer patients. They 
provide a better understanding between the link in obesity and breast cancer risk. 
 
1.4.1 Types of Mouse Models Used In Cancer Research 
Over the past years researchers have developed numerous genetically engineered mouse 
models to study human breast cancer. The advantage of using mouse models in breast 
cancer research is their ability to be manipulated easily and they have a short generation 
period (91). The other advantage is their physiology and metabolism more closely mimics 
the human physiology and metabolism than any other animal model (91).  
 
The most commonly used mouse models in breast cancer research are xenografts and 




which the tumour originated into immune compromised (nude) mice or severely 
compromised immunodeficient (SCID) mice that do not reject human cells (91). On the 
other hand, in syngrafts models only tumour cells from the same genetically identical 
members can be inoculated into the organ type which tumour cells originated, into fully 
immune competent mice (BALB/C and C57BL/6); (92). 
1.4.2 Obese Mouse Models in Breast Cancer Research 
Over the past years researchers have used either genetic or diet induced obese mouse 
models to explore the links between obesity and breaks cancer risk (Table 2). 
Ovariectomized mice whose ovaries have been surgically removed have been used to 
explore the links between obesity and breast cancer risk at postmenopausal status (93, 94).  
 
A study on a syngeneic mouse model of EO771 mammary tumour fed on a high fat diet 
(HFD) had a shorter tumour latency period and increased tumour growth than their lean 
counter parts fed on a low fat diet (LFD); (93). The tumours from the obese mice were 
heavier than non-obese mice. The study also reported that obese mice had elevated levels 
of plasma VEGF than their lean counter parts that is associated with increased tumour 
proliferation and survival (93). 
 
On the other hand Chung et al (95) used transgenic heterozygous (+/ob) and ob/ob mice to 
investigate the role of diet-induced obesity on breast tumour growth and development. 
They reported that ob/ob mice on HFD were heavier than heterozygous (+/ob) and wild 
type mice (95). Interestingly they found no significant difference in tumour growth rates 
between the three different groups fed a HFD despite the ob/ob mice being heavier (95). 
TNF-α level were overexpressed in obese mice compared to lean mice regardless of the 
group (95) The study implicates that obesity is associated with a higher inflammatory state 
however it did not have any effect on tumour growth. 
 
A study done by Nunez et al. (96) explored the links between obesity and breast cancer risk 
on menopausal status. They reported that diet induced obesity increased mammary 
tumour development in mice that mimicked postmenopausal status (96). On the other 
hand obesity did not affect tumour growth in mice that mimicked premenopausal status 
(96). Another study using young immune compromised Rag-1 C57BL/6J MCF-7 or MBA-MD-




independent of the ER status (97). They reported that there was no significant difference in 
mammary tumour development between obese and non-obese young female mice (97). 
This suggests that obesity is a risk factor in receptor positive breast cancer development in 
postmenopausal status but not at premenopausal status.  
  
Obesity affects breast cancer risk by triggering both adipocyte recruitment and activation 
of macrophages in breast tumour microenvironment (80). Diet induced obese humanized 
mouse model of breast cancer developed by injecting stromal vascular fraction (SVF) into 
MFP of NOD/SCID mice had increased tumour growth (98). The study reported that obesity 
induces recruitment of macrophages in the breast tumour, which is associated with 
increased angiogenesis that supports tumour growth and survival (98).  
  
Transgenic MMTV-TGF-α mice with a C57BL/6 genetic background develop ER+ breast 
tumours, due to overexpression of TGF-, and at 16 months of age, these mice mimic the 
postmenopausal status among the female human population (99). On the other hand, 
under the same experimental conditions, FVB/N MMTV-neu mice have ER negative breast 
tumour phenotype due to over expression of the neu gene (100). MMTV-TGF-α on HFD had 
increased mammary tumour development than mice on a LFD (99).  However in MMTV-
neu mice there was no significant difference in mammary tumour development between 
mice on a HFD or a LFD (100). The difference in results was proposed to be due to the 
genetic background of MMTV-neu mice as FVB/N mice are resistant to obesity (101). 
 
Khata et al explored the role of estrogen in obesity related breast tumour development 
(102). Obesity in these mice was initiated by injecting goldthioglucose as opposed to a HFD 
(102). They reported that estrogen had a protective role on tumour development in obese 
mice with supplementary estrogen compared to mice without supplementary estrogen 
(102). Overall, obese mice had increased mammary tumour development compared to lean 






Table 2: Summary of obese mouse models used to show the relationship between obesity and breast cancer risk 
Source                     Mouse Model                      Tumour Model                                                                                Main Findings 
Khata et al. (102) CD-1 nude mice  T47-D Mammary tumour development increased in obese ovariectomized mice 
without supplementary estrogen 
Arendt et al. (98) Humanized NOD/SCID mice  Obesity increases risk of breast cancer in postmenopausal state by CCL2-
mediated macrophage recruitment and angiogenesis forming aggressive 
tumours 
Ray et al. (97) Rag -1 C57BL/6J mice  MCF-7 or MBA-MD-231 No effect of obesity on mammary tumour development with ER negative 
(MDA-MB-231) and ER positive (MCF-7) cell line 
 
Cleary et al. (100) MMTV-Neu FVB/N mice  Obesity did not affect ER negative mammary tumour development 
 
Gu et al. (93) Ovariectomized C57BL/6 E0771 Postmenopausal obesity increased breast tumour angiogenesis and growth. 
VEGF was overexpressed in obese mice compared to lean. 
 
Alikhani et al. (103) ApoE knockout C57BL/6 mice  Met1 or Mut1 Female mice on high fat high cholesterol diet had increased tumour growth 
and distant metastasis compared to lean counterparts 
 
Nunez et al. (96) C57BL/6 mice  Wnt-1 mice tumour cells Diet induced obesity enhanced breast tumour growth in ovariectomized mice 
but not in non-ovariectomized mice 
 
Pelton et al. (104) SCID mice  MDA-MB-231 Obese mice expressed fastest tumour growth compared to non-obese mice  
 
Chung et al. (95) Ovariectomized Heterozygous 
(+/ob), ob/ob C57BL/6J  
Py230 Obesity promoted breast tumourigenesis in high fat diet mice 
Cleary et al. (99) C57BL/6  
MMTV-TGF α mice 






Alikhani et al. (103) studied breast tumour growth in homozygous ApoE -/- mice.  These 
mouse models are widely used to study atherosclerosis and disorders associated with 
dyslipidaemia (103).  Apo lipoprotein E (ApoE) is a major constituent in HDL and 
triglyceride rich lipoproteins (103). ApoE plays a major role in the catabolism of 
triglycerides and cholesterol, and a variation in the ApoE gene causes alteration in plasma 
lipid levels (103). ApoE deficient (ApoE -/-) mice have increased levels of plasma 
triglycerides, and HDL cholesterol and are more susceptible to atherosclerosis (103). 
ApoE -/- mice when fed with a high cholesterol diet showed increased breast tumour 
growth and metastasis to lungs compared to wild type mice (103). ApoE -/- mice showed 
some signs of metabolic syndrome such as elevated cholesterol levels but maintained 
normal glucose homeostasis (103). 
 
Scott et al. developed a double knock out ApoE/ArKO mouse model with metabolic 
syndrome (105). The double knock out ApoE/ArKO mouse model has a deficiency of Apo 
E and aromatase that, catalyses the conversion of androgens to estrogen (105). They 
found that ApoE/ArKO mice showed significant signs of increased obesity at the early age 
of 10 weeks compared to ApoE mice (105). On average, 6-month-old female mice with 
metabolic syndrome were 6 grams heavier than the wild type mice and had significant 
signs of metabolic syndrome (105). The ApoE/ArKO phenotype exhibited central obesity, 
increased serum lipid levels, atherosclerosis, insulin resistance, intolerant glucose level 
and inflammation (105). These signs of metabolic syndrome correspond to human 
metabolic syndrome and therefore provide a novel animal model (105). However, no 
studies have been done to see the effect of all the disorders of metabolic syndrome on 




1.5 Research Objectives 
Human association studies have provided insight into understanding the different roles of 
metabolic syndrome factors in tumour growth. However there is a limitation to these 
studies, as patients in these clinical studies were not manipulated. On the other hand 
cells in in vitro studies can be manipulated but lack the complexity and dynamics of the 
whole organism. Currently there are no in vivo studies that have explored the role of 
metabolic in breast tumour initiation and growth. Hence a novel animal model with 
metabolic syndrome that mimics human metabolic syndrome is required to further 
explore the relationship between metabolic syndrome and breast cancer. Tumours need 
to be characterised in order to obtain therapeutic targets for aggressive, obesity-
associated tumour. 
 
The aim of the study was to develop an obese metabolic mouse model of breast cancer 
ApoE/ArKO and an obese dysfunctional cholesterol mouse model of breast cancer ApoE 
to study early stage breast cancer. The mouse model was used to study: 
1. Tumour growth rates and mouse physiology. 
2. CAA and secreted proteins. 
3. Characterize the morphology of the tumour. 







2 Materials and Methods 
2.1 Mouse Model 
Ethics approval for this study was obtained from the University of Otago Animal Ethics 
Committee (C05/14). International guidelines for animal welfare were strictly followed 
(UKCCCR). 
 
Wild type and transgenic (ApoE and ApoE/ArKO) C57BL/6 mice were obtained from the 
University of Otago, Christchurch. The ApoE/ArKO mice were bred in house (University of 
Otago, Christchurch) from heterozygous aromatase deficient Ar+/-C57BL/6 and 
homozygous ApoE deficient (ApoE-/-) C57BL/6 mice and genotyped by PCR as described 
previously (105) by Dr Nicola Scott. The mice were subjected to reverse 12:12 hour dark-
light cycle. A maximum of 5 mice were housed in a cage and cages were cleaned every 
after 3-6 days depending on number of mice. Mice were fed a normal chow diet and 
supplied with sufficient food and fresh water. 
 
2.2 Cells 
EO771 cells are a medullary breast adenocarcinoma cell line derived from C57BL/6 mice. 
This cell line was supplied by Dr Andreas Moeller, QIMR Berghofer, Australia and stored 
frozen in cryopreservation media (Dulbecco’s Modified Eagle’s Medium (DMEM), 20% 
FCS, 10% dimethyl sulfoxide (DMSO)) in vapour phase of liquid nitrogen until use.  
 
2.2.1 Tumour Model 
At 25-52 weeks of age, mice were orthotopically inoculated with 2 x 105 E0771 cells 




This procedure was carried out under isoflurane anaesthesia by A/Prof Gabi Dachs. Mice 
were weighed and monitored using Animal Welfare Sheets and tumour was measured 
daily for 15-20 days after tumour implantation. Tumuors were measured using caliper 
measurements and volume calculated by modified episodial formula (Section 9.2) 
 
2.2.2 Organ Harvest from Mice 
After tumour had reached a maximum volume of 200 mm3, or after 15-20 days, mice 
were sacrificed. Mice were euthanized by isoflurane overdose and cervical dislocation 
(this procedure was carried out by A/Prof Gabi Dachs). At 90 minutes prior to tumour and 
organ harvest, mice were injected with 2 µL/g of body weight with Pimonidazole, a 
hypoxia marker, at a concentration of 30 mg/mL (final 60 mg/kg). Mice were dissected 
carefully and examined for any organ abnormalities or internal metastases. Kidney, liver, 
primary tumour, MFP, internal fat and blood was collected from each.  Ascites and 
secondary tumours were collected from mice with metastasis. Blood was centrifuged at 
4000 x g for 10 minutes (C7600-Innova, Eppendorf, UK), and plasma was collected and 
frozen down along with the ascites fluid at -80°C. Kidney, liver, primary tumour, 
secondary tumour and internal fat was weighed for each mouse. Liver, primary tumour, 
secondary tumour and MFP was cut into half, one half was formalin fixed and the other 
half frozen down to -80°C (C7600-Innova, Eppendorf, UK). Kidney and internal fat was 
discarded after the weight was recorded. 
2.3 Cell Culture 
EO771 cells were maintained in phenol red containing DMEM with GLUTaMaxTM and 
4.5g/L-D Glucose and no sodium pyruvate (Gibco) supplemented with 10% Fetal Bovine 
Serum (FBS) (Thermofisher) and antibiotic-antimycotic solution (Thermofisher) in a 5% 
CO2 containing humidified incubator at 37°C. After 24 hours, media was removed; cells 
were washed with media and replaced with fresh media. At 70% confluence, cells were 
detached from the flask by trypsinization. Media was removed first, washed by PBS 
(0.01M Phosphate buffer, 0.0027M Potassium Chloride, 0.137M Sodium Chloride, pH 7.4 
from Sigma Aldrich) and then TrypLETM Express (Gibco) was added. The flask was 
incubated in humidified chamber at 37°C for 5-10 minutes. The cells were replated at a 




To prepare cells for tumour implantation, cells were detached from flask by trypsinization 
as previously stated. Cells were spun down 3 times at 500 x g for 5 minutes, and after 
every spin, the supernatant was discarded and cells resuspended in 5mL of PBS. Cells 
were counted and the final concentration for 1 x1 06 EO771 was inoculated into the 4th 
MFP of each mice. 
 
2.3.1 HIF-1α Expression in EO771 
Hypoxia inducible factor 1-alpha (HIF-1α) is a subunit of the transcription factor HIF-1 that 
is involved in cellular response to low oxygen conditions.  
 
2.3.1.1 Cobalt Chloride 
Expression of HIF-1α in EO771 cells was chemically induced by 100 mM of CoCl2. At 90-
100% confluence, cells were reseeded in 6 well plate with 2 mL of media in each well. 10 
µL of 20 mM of CoCl2 was added to each well making the final concentration to 100 mM. 
One plate was used as a control without cobalt chloride. Both the plates with and without 
cobalt chloride were placed in a 5% CO2 containing humidified incubator at 37°C for 5 
hours.  
 
2.3.1.2 Hypoxia Chamber 
The hypoxia chamber (Hypoxystation H35, Don Whitley scientific (UK)) was calibrated 
according to manufacturer’s instruction before carrying out the experiment. At 80-90% 
confluence (2 x 106), cells were reseeded in a 6 well plate inside the hypoxia chamber. 
Two mL of cell culture media was added to each well. The cells were maintained under 
hypoxic conditions in a 1% oxygen and 5% CO2 containing hypoxic chamber at 37°C for 24 
hours. 
 
For the negative control, cells were seeded in a 6 well plate under normal oxygen 
conditions. The plated was incubated in a 5% CO2 containing humidified incubator at 37°C 





2.3.1.3 Cell Lysis 
Cell lysis of EO771 cells was carried out on ice. Media was removed from each well and 
cells washed twice with PBS. After the wash step, 150 µL of radio immunoprecipitation 
assay (RIPA) lysis buffer (Section 9.1.4) plus Protease Inhibitor Cocktail (PIC) was added to 
each well and cells were scraped from each well and pooled. Cell were lysed and 
homogenised with a 24G needle and centrifuged down for 10 minutes at 10000 x g at 
4°C.  EO771 cells that were subjected to hypoxic conditions were lysed inside the hypoxia 
chamber. 
2.4 Frozen Tissue Grinding 
Sufficient amounts of frozen primary and secondary tumour tissue was bathed in liquid 
nitrogen and ground into a fine powder using cold mortar and pestle placed on dry ice. 
The finely ground tissue was suspended in RIPA buffer (Section 9.1.4) and centrifuged 
down at 4°C for 10 min at 10000 rpm (Eppendorf Centrifuge 5417R, Germany).  The 
supernatant, tumour tissue lysate, was collected. An aliquot was taken for BCA assay and 
the rest frozen down to -20°C. 
 
2.5 Western Blot 
Western blot is a semi quantitative analytical technique used to detect the amount and 
size of a protein present in a tissue or a cell lysate by using specific antibodies to detect 
the protein of interest. This technique was used to analyse the expression of HIF-1α in 
cell culture and tumour samples. 
 
2.5.1 Protein Measurement by BCA Assay 
The amount of protein present in the tumour tissue lysate was measured using a Thermo 
Scientific Pierce®BCA protein Assay Kit. A set of protein standards were made using a 2 
mg/mL of Bovine Serum Albumin (BSA) stock solution (Table 3) and the diluent used was 







Table 3: Preparations for diluted BSA standards 
Vial Volume of RIPA 
Lysis Buffer (µL) 
Volume and 




A 0 300 of Stock 2000 
B 125 375 of Stock 1500 
C 325 325 of Stock 1000 
D 175 175 of vial B 750 
E 325 325 of Vial C 500 
F 325 325 of Vial E 250 
G 325 325 of Vial F 125 
H 400 100 of Vial G 25 
I 400 0 0=Blank 
 
A volume of 25 µL of each standard and unknown sample in duplicates was placed into a 
96 well micro plate. A volume of 200 µL of working solution (50 parts Reagent A: 
Bicinchoninic Acid (Sigma) and 1 part Reagent B: Pierce® BCA protein Acid Reagent 
(Thermo Scientific)) was added to the sample, and the plate was incubated for 30 min at 
37°C. After incubation, the absorbance was measured at 562 nm on a plate reader 
(Thermo Scientific). 
 
An average absorbance for each known sample was subtracted from the average 
absorbance of the blank sample. These values were used to plot a standard curve as 
shown in Figure 7. Concentrations of unknown samples were determined from the 






Figure 7: A representative standard curve showing Absorbance of BSA at 562nm.  
The curve is used to calculated unknown sample concentrations. 
 
2.5.2 SDS-Page Gel Electrophoresis 
Sample for western blot analysis was prepared by using tumour tissue lysate at a 
concentration of either 1 or 2 µg/µL (depending on the protein concentration), 0.1 M DTT 
(Sigma Aldrich), x1 LeammLi Sample Buffer (LDS); (Bolt System) and RIPA buffer (Section 
9.1.4) was added until a final volume of 50 µL was reached as shown in Table 4. 
 





Volume of RIPA 
(µL) 
Volume of 
x10 DTT (µL) 
Volume of 
x4 LDS (µL) 
Final volume of 
sample (µL) 
1 or 2 
X= 50 -(Volume 
of DTT + LDS + 
lysate) 
5 12.5 50 
 
The samples for western blot were heated for 10 minutes at 70°C and 10 µg of protein 
and was loaded into BoltTM 4-12% Bis-Tris plus 12 well gels (ThermoFisher). Each gel 
contained a ladder, and a positive control. The samples were run at 125 mV for 75 
minutes using 1xNuPage MOPS SDS Running Buffer (ThermoFisher). 

























2.5.3 Transfer of Proteins 
Polyvinylidene fluoride (PVDF) membrane was activated with methanol and washed with 
MilliQ-water. PVDF membrane and filter paper were soaked in 1x BoltTM transfer buffer 




Figure 8: Representation of gel and membrane assembly for transfer of proteins from SDS gel 
to PVDF membrane 
The above diagram shows the construction of the gel membrane “sandwich” for protein transfer 
 
 
Protein transfer from gel onto PVDF membrane from gel was carried out using 1x BoltTM 
transfer buffer and cold water at 25 mV for 75 minutes. For nonspecific binding of 
antibodies, membranes were blocked with 5% milk in 1xTris-buffered Saline with 0.1% 
Tween 20 (TBS-T, Sigma, Section 9.1.5) for 60 minutes at room temperature.  
 
2.5.4 Antibodies 
Primary antibodies were diluted in 5% milk in TBS-T (Table 5) and were incubated gently 
agitating overnight at 4°C. The membranes were subjected to three 5 minute washes 
with TBS-T. Secondary antibodies were diluted in 5% milk in TBS-T (Table 5) and were 
incubated gently agitating for 60 minutes at room temperature. The membranes were 




























































Blots were developed with "Enhanced ChemiLuminescent Kit" (ECL, Amersham) as per 
manufacturer’s instruction, and visualised using UVItec Alliance 4.7 imaging machine 
(UVItec, Cambridge, UK). 
2.5.5 Western Blot Stripping 
In order to detect different antigens, membranes were stripped and reprobed with the 
appropriate antibody. For in vitro analysis, blots were probed for HIF-1α followed by 
GLUT-1 and then β-actin. Membranes were stripped twice using stripping buffer (Section 
9.1.6) for 5 minutes rotating. Stripping buffer was removed and the membrane was 
equilibrated in PBS (2 x 10 minutes). After the final PBS wash, membranes were further 
washed in TBST (2 x 10 minutes), before the membrane was blocked (5% skim milk in 
TBST) and the appropriate primary antibody was added to the membrane (Table 5). 
2.5.6 Band Quantification 
Multiple exposure times were used to visualize band exposure. Protein bands were 
quantified using the Alliance 2.7 software (Uvitec, Cambridge, UK). Each band was 




2.6 Adipokine Array 
A range of adipokines was measured in tumour lysates by using a mouse adipokines array 
kit according to manufacturer’s instructions as follows (R&D Systems, Minneapolis, MN). 
Nitrocellulose membranes were blocked with array buffer 6 and incubated for 1 hour 
rotating at room temperature. After incubation 400 µg of protein sample from tumour 
lysate was added to 0.5 mL of Array buffer 4 and the final volume was adjusted to 1.5 mL 
with array buffer 6 followed by the addition of 15 µL of diluted antibody was added to 
each sample and incubated at room temperature for one hour. After one hour, the 
blocking buffer was aspirated and the sample/antibody mixture was added and incubated 
overnight at 4°C on a rotating platform. After overnight incubation the membranes were 
washed thrice for 10 minutes with 1x wash buffer. Diluted streptavidin conjugated with 
horseradish peroxidase (HRP) (1:2000) was added to each membrane and incubated for 
30 minutes gently agitating at room temperature. After incubation membranes were 
washed thrice with 1x wash buffer for 10 minutes gently agitating. Excess wash buffer 
was removed and 1 mL of chemi reagent mix (ratio 1:1) was added and membranes were 
visualised using UVItec Alliance 4.7 imaging machine. 
 
Multiple exposure times were used to visualize each spot to ensure signal was within the 
linear range. Adipokine spots were quantified using the Alliance 2.7 software. Each spot 
was normalised by dividing the average signal of each spot by the average signal of the 
three reference spot. 
 
2.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
2.7.1 Insulin-like Growth Factor Binding Protein 5 ELISA 
An ELISA assay was used to measure IGFBP5 protein concentrations in tumour lysates and 
plasma in accordance to the manufacturer’s specification (Abcam, Cambridge, Uk). 100 
µL of each sample or standard was added to a 96-well plate pre-coated with mouse 
IGFBP5 antibody. The plates were incubated at room temperature for 2.5 hours, then 
washed four times with 1x wash buffer and 100 µL of detection antibody was added and 
incubated for 1 hour at room temperature. The plate was washed four times with wash 




minutes at room temperature. The plate was washed four times with wash buffer and 
added 100 µL of tetramethylbenzidine (TMB) was added to each well and incubated for 
30 minutes at room temperature on a rotating platform. The addition of 50 µL of stop 
solution to each well stopped the reaction. Absorbance was measured at 450 nm and 
corrected by subtracting measurements at 540 nm using a Varioskan™ Flash Multimode 
Reader (Thermo Scientific, Waltham, MA, USA). The IGFBP5 protein concentration was 
calculated from a linear standard curve ranging from 7.8 - 3300 pg/mL of purified IGFBP5 
as supplied with the kit.  
2.7.2 Vascular Endothelial Growth Factor ELISA 
An ELISA assay was used to measure vascular endothelial growth factor (VEGF); (R&D 
Systems, Minneapolis, MN) concentrations in tumour lysates and plasma in accordance to 
the manufacturer’s specification. A volume of 100 µL of capture antibody was added to 
each well and incubated at room temperature overnight. The capture antibody was 
washed three times in PBS with 0.05 % (v/v) Tween®-20 (PBST) wash buffer and 300 µL of 
blocking reagent was added (1% BSA in PBS) and incubated for 1 hour at room 
temperature. After incubation each well was washed with thrice PBST was buffer, and 
100 µL of each sample or standard was added to a 96-well plate coated with either the 
primary mouse VEGF antibody. The plates were incubated at room temperature for 2 
hours, and then washed three times in PBST wash buffer 100 µL of detection antibody 
was added and incubated for 2 hours at room temperature. The plate was washed thrice 
with PBST wash buffer and 100 µL of streptavidin conjugated with HRP was added and 
incubated in the dark for 20 min at room temperature. The plate was washed thrice with 
PBST wash buffer and 100 µL of the substrate solution (1:1 hydrogen peroxide and 
tetramethylbenzidine (TMB)) was added to each well. The plate was incubated for 20 
minutes at room temperature in the dark. The addition of 50 µL of hydrochloric acid to 
each well stopped the reaction. Absorbance was measured at 450 nm and corrected by 
subtracting measurements at 540 nm using a Varioskan™ Flash Multimode Reader 
(Thermo Scientific, Waltham, MA, USA). The VEGF protein concentration was calculated 
from a linear standard curve ranging from 15.6 - 1000 pg/mL of purified VEGF-A, as 







Canterbury Health Laboratories embedded the formalin fixed tissue. Formalin fixed and 
paraffin embedded (FFPE) tissue samples were cut into 10 consecutive sections at 3-4 µ 
each by Gribbles, Christchurch, NZ. EO771 tumours were analysed for estrogen receptor 
status by using an antibody against Estrogen Receptor alpha (ERα). An optimum 
concentration of 1:100 was used (Table 6). Each slide was analysed for presence of 
cancer-associated adipocytes. An optimum concentration of 1:800 of perilipin antibody 
that binds to the lipid membrane was used (Table 6). Only tumour embedded slides were 
analysed for tumour cell proliferation. An optimum dilution of 1:100 of Phosphohistone – 
H3 (pHH3) was used (Table 6). The source of antibodies used for immunohistochemistry 
is stated in Table 6. The Immunohistochemical labelling was performed using the single 
stain EnVisionTM G|2 System/AP Rabbit/Mouse visualization kit. The kit includes 
Rabbit/Mouse Link, AP enzyme enhancer, permanent red substrate buffer and 
permanent red chromogen (Dako, Denmark A/S). 
 
2.8.1 Rehydration and Antigen Retrieval 
Slides were baked at 60°C for 2 hours for firm attachment of tissue. Slides were 
deparaffinised and rehydrated by subjecting them to two 5 minutes washes in xylene, 
two 3 minutes washes in 95% ethanol, two 1 minute washes in Milli-Q water. Slides were 
incubated in 1 x PBS (Section 9.1.1) until antigen retrieval step was performed. The 
antigen retrieval, 1 x Citrate buffer (pH 6); (Section 9.1.3) was added to the pressure 
cooker. Slides were transferred into the pressure cooker once boiling. The slides were 
incubated in cooker for 3 minutes at maximum pressure. After incubation, slides were 
cooled in cooker for 40 minutes. Slides were subjected to two 2 minutes washes in 1 x 
PBS-Tween 20 (PBST, Section 9.1.2). Slides were drained and placed in a humidified 
chamber. A barrier was drawn around the tissue to concentrate reagent and 200 µL of 
Dual Endogenous Enzyme Block (Dako, Denmark A/S) was applied to cover specimen. The 
slides were incubated in humidified chamber at room temperature for 5 minutes. After 






Primary antibodies were diluted in 1 x PBS in the appropriate ratio (Table 6). A final 
volume of 200 µL of diluted primary antibody was applied to cover specimen. For 
negative control 200 µL of 1 x PBS was applied. Slides were incubated overnight at 4°C.   
 
Table 6: Primary and secondary antibody concentration used for immunochemistry analysis 
Primary  
Antibody 













histone – H3 










Slides were subjected to three 5 minute washes in PBST and 200 µL of secondary 
antibody, Rabbit/Mouse LINK was applied to cover all slides including the negative 
control. Slides were placed in humidified chamber at room temperature for 30 minutes. 
After incubation, slides were subjected to two 5 minutes washes in PBST and 200 µL of 
polymer/AP was applied to cover slides and incubated for 10 minutes at room 
temperature in humidified chamber. After incubation, slides were washed for 5 minutes 
twice in PBST. Permanent red working solution prepared by mixing 1 mL of permanent 
red substrate buffer and 10 µL permanent red chromogen was mixed 5 minutes prior to 
application. After the final was step, 200 µL of permanent red solution was applied to 
cover all specimens and incubated at room temperature in humidified chamber for 10 
minutes. After incubation, excess permanent red working solution was tapped off and all 





2.8.3 Manual Counterstaining and Cover Slipping  
Manual counterstaining was performed consecutively as follows by: all the slides were 
immersed in haematoxylin for 45 seconds, rinsed with tap water, placed it in acid/alcohol 
for 5 seconds, rinsed in tap water and finally immersed in Scott’s water for 20 seconds. 
Slides were dehydrated through consecutive immersion in 95% isopropyl alcohol (IPA), 
100% IPA, 100% IPA, xylol and xylol. Slides were left submerged in xylol until ready for 
cover slipping. Slides were cover slipped using an automated system (Leica Autostainer XL 
& Leica CV5030). 
 
2.8.4 Quantification of Immunohistochemistry Staining 
Perilipin and pHH3 positive cells were quantified from 20 random fields and were 
calculated as a percentage of tumour cells. Pimonidazole staining was quantified by the 
degree of staining and area stained (Section 9.3). 
2.9  Statistical Analysis 
Data were analysed using SPSS 20.0 and Graph pad software (version 5). Data were 
analysed using 1way ANOVA followed by Newman-Keuls and Bonferroni multiple 
comparison tests. Correlation data was analysed by spearman correlation. Student’s t-





3 Mouse Physiology and Tumour Growth 
3.1 Chapter Aims 
Epidemiological studies have shown a correlation between obesity and breast cancer risk. 
Although there are various potential mechanisms been proposed linking obesity and 
breast cancer but this relationship has not yet been fully evaluated (3, 20, 56, 69, 98, 106, 
107). The aim of this chapter was to evaluate the effects of dysfunctional cholesterol 
metabolism and metabolic syndrome on breast tumour initiation, growth and 
progression using a syngeneic knockout mouse model. 
3.2 Experimental Design 
The three groups of mice (wild type, ApoE and ApoE/ArKO) between the ages of 26 – 52 
weeks were inoculated with murine breast cancer cell line (EO771 (1 x 106)) 
subcutaneously into the fourth mammary fat pad (MFP). Once tumours were established 
they were measured daily using callipers until ethical end point. Tumour volume was 
calculated using the modified ellipsoidal formula (section 9.2). 
 
The experiments in this chapter involved; 
1. Measuring mouse weights daily post tumour implant until ethical end point. 
2. Harvesting and weigh organs (liver, tumour, omental fat and kidney) to determine 
any significant difference. The organs were formalin fixed and paraffin embedded  
(FFPE) for immunohistochemistry analysis and frozen down for further analysis. 








3.3.1 Mouse Weights 
The average mice weight during the tumour-bearing period is shown in Figure 9. Mice 
weight differed by 2 g before tumour burden and end point. The ApoE mice were the 
heaviest compared to the wild type and ApoE/ArKO mice (Figure 9). On average the wild 
type mice weighed 25.4 g ± 0.4 g (n=15), ApoE 27.6 g ± 0.5 g (n= 5) and ApoE/ArKO 24.0 g 
± 0.8 g (n=9). The ApoE mice were on average 2.2 g ± 07 g heavier than the wild type and 
3.6 g ± 0.9 g than the ApoE/ArKO mice. There was no significance difference in weight 
between the wild type and ApoE/ArKO mice. 
 
 
Figure 9: Mouse weight of wild type, ApoE and ApoE/ArKO during the tumour bearing period. 
The graph shows the comparison of the average mouse weights of Wild type (n= 15), ApoE (n= 
15) and ApoE/ArKO (n=9) during the tumour bearing period. Data is represented as a mean and 
standard error of mean. Data were analysed using 1way ANOVA followed by Newman-Keuls and 
Bonferroni multiple comparison tests. ** p<0.01, ***p<0.001 
 
3.3.2 Mouse Organ Weights 
There was no significant difference in the average kidney (p=0.812), liver (p= 0.113) and 
omental fat (p=0.359) weight between the wild type, ApoE and ApoE/ArKO mice (Figure 
10). However, there was a trend for the ApoE mice organs to be heavier and ApoE/ArKO 
mice organs to be smaller. Tumour weights also were not significantly different between 
Mouse  Weights




















the three groups of mice, although this was expected as tumours were harvested once 




Figure 10: Kidney, liver, omental fat and tumour weight of Wild Type, ApoE and ApoE/ArKO 
mice. 
The graph above shows the weight of (A) Kidney, (B), liver, (C) omental fat and (D) tumour of the wild type 
(n=15), ApoE (n=15) and ApoE/ArKO (n=9) mice. Data is represented as a mean and standard error of mean. 




Wild type (n=3) and ApoE (n=3) mice had internal metastases from primary EO771 
tumours but no internal metastasis was observed in the ApoE/ArKO mice (Table 7) .All 
the ApoE mice (n=3) with internal metastases had a primary tumour. Only two out of 
three wild type mice with internal metastases had a primary tumour. Metastases were 
observed throughout the abdominal cavity. There was no significant difference observed 
in the weight of the internal metastases from ApoE and wild type mice. On average the 
internal metastases from both groups of mice was 1.2 g ± 0.3 g. Ascites fluid was also 

















































































collected from the wild type and ApoE mice. On average between 600 µL – 800 µL was 
collected. 
Table 7: Representation of the percentage of mice with EO771 primary or internal metastases. 
The percentage of mice with no tumour burden is shown as well. 
 
Mouse Type Number of mice 
implanted with 
EO771 cells (%) 
Number of mice 
with primary 
tumours (%) 




no tumour (%) 
wild type 15 (100%) 13 (87%) 3 (20%) 1 (7%) 
ApoE 15 (100%) 11 (73%) 3 (20%) 2 (12%) 
ApoE/ArKO 9 (100%)                                                 8 (89%) 0 (0%) 1 (11%) 
 
 
3.3.3 Tumour Growth Rates 
Tumour growth was highly variable in each of the three-mouse group with no clear trend 








Figure 11: The growth of EO771 tumours in wild type, ApoE and ApoE/ArKO mice. 
Mice were injected subcutaneously with cultured EO771 cells (1 x 106 cells/mouse) into the 4th 
MFP. Tumour size was measured daily. The data shown is the raw data for tumour growth post 
EO771 injection over a period of 15-25 days. Tumour growth of (A) wild type mice (n=15), (B) 







There was no significant difference observed in the lag phase of tumour growth (time for 
the tumour to reach 50 mm3) and log phase of tumour growth (time for the tumour to 
reach 4x volume i.e. from 50-200 mm3) in the wild type (n=15), ApoE (n=15) and 
ApoE/ArKO (n=9) mice (Figure 12). 
 
The ApoE mice appeared to have the fastest tumour establishment whereas the 
ApoE/ArKO mice had the fastest tumour growth, although the differences between them 
were not statistically significant. The older ApoE mice had a longer tumour latency period 
than the younger ApoE mice. Note: only 6 out of the 9 ApoE/ArKO mice reached a 




Figure 12: Tumour growth rates defined as lag phase and log phase 
Tumour growth rates defined as lag phase (time it takes for the tumour to reach 50 mm3) and log 
phase (time it takes for tumour to reach 4X volume i.e. 50-200 mm3). There was no significant 
difference observed at both the lag and log phase of tumour growth. Data were analysed using 
1way ANOVA followed by Newman-Keuls and Bonferroni multiple comparison tests. 
 
3.4 Discussion 
Obesity has been shown to increase breast tumour initiation and progression however 
the mechanisms still remain to be critically evaluated (20, 53, 56). In order to be classified 
as obese there should be a minimum difference of 17% in body mass index (BMI), which 
is a measure of body weight over height squared (kg/m2); (108). In humans normal BMI 
ranges from 20 -25 and obese BMI ranges from 30 and above (108). In the present study 

























The ApoE mice were on average 8% heavier than wild type mice and 13% heavier than 
ApoE/ArKO mice. There was also no significant difference observed in the percentage of 
omental fat to body weight in the three groups of mice (Figure 13). 
 
 
Figure 13: Percentage of omental fat to body weight of wild type, ApoE and ApoE/ArKO mice. 
The graph shows percentage of omental fat to body weight of wild type (n=14), ApoE (n=14) and 
ApoE/ArKO (n=9) mice. Data is represented as a standard error of mean. Data were analysed 
using 1way ANOVA followed by Newman-Keuls and Bonferroni multiple comparison tests. 
 
Dysfunctional cholesterol metabolism in ApoE mice and metabolic syndrome in 
ApoE/ArKO mice did not have a significant impact on tumour initiation and progression as 
all the mice had a similar tumour growth rate. All the three groups of mice had a similar 
physiology as no difference was observed in their organ weights. The probable cause for 
no difference observed in tumour growth rates between the three groups of mice might 
have slightly been contributed to the technique used for tumour measurement. Calliper 
measurement is not an accurate technique used to measure tumour volumes. Imaging 
techniques such as magnetic resonance imaging (MRI), optical imaging, ultra sound and x-
ray computed tomography (CT) provide an accurate measurement of tumour volume 
however they are expensive and not available for small animal work (109). 
 
Scott et al (105) reported that the ApoE/ArKO mice at all stages of life (3, 6 and 12 
months) were heavier than the C57BL/6 wild type mice and especially at 6 months of age 
the ApoE/ArKO mice were 6 grams heavier than wild type mice. However this was not 
observed in this study. In fact the ApoE/ArKO mice were on average 1 gram lighter than 































the wild type mice before and post tumour implant. The ApoE/ArKO mice were 
genotyped so certain they were the correct mice. This suggests that tumour burden was 
not the cause for the ApoE/ArKO mice being smaller than expected. The mechanisms as 
to why the ApoE/ArKO mice were smaller than expected remains unclear and needs 
further investigation.  
 
Dysfunctional cholesterol has been reported to increase cardiovascular diseases (CVD), 
inflammation and diabetes that become more prevalent at old age (110). It was expected 
that older ApoE mice would have a shorter tumour latency period than younger ApoE 
mice due to dysfunctional cholesterol, although it was apparent that older ApoE mice had 
a longer tumour latency period. It has been reported that CVD increases the incident of 
breast cancer in human (111) however the association in mouse model is obscure. 
 
It was also observed that the ApoE/ArKO mice had the highest number of tumour 
regression compared to the ApoE and wild type mice. The proposed reason for this action 
might be due to an immune response. This supports the fact that none of the ApoE/ArKO 
mice had internal metastases compared to wild type (n=3) and ApoE (n=3) mice. There is 
a conflict in the literature regarding the metastatic characteristic of the EO771 cells. Ewen 
et al (112) have reported that EO771 invades into the peritoneum and lung whereas 
Johnstone et al reported that EO771 poorly metastasise (113). In the current study 83% 
of the mice with internal metastases had a primary tumour, suggesting that EO771 cells 








4  Characterization of Tumour Pathology. 
4.1 Chapter Aim 
The aim of this chapter was to characterise the tumour ER status and tumour histology of 
ER status, tumour proliferation and intratumoural fat (CAA)  
The experiments in this chapter were designed to determine: 
1. Differences in tumour proliferation and CAA between the wild type, ApoE and 
ApoE/ArKO mice by immunohistochemistry analysis.  
2. ER status of the EO771 tumours. 
4.2 Experimental Design 
FFPE tissue samples were assessed for ER status, cancer associated adipocytes and 
proliferation. ER status was assessed using an antibody against estrogen receptor alpha 
(ERα) which is a nuclear receptor activated by estrogen (98). The ERα antibody binds to 
the nucleus of the cell if the tumour is ER+ (98). The anti-ER antibody used in the 
current study recognizes both human and mouse EROptimization of anti-ER antibody 
dilution was performed on human breast cancer samples. The ERα antibody dilutions 
used were 1:20, 1:50 and 1:100, where 1:100 was the optimum concentration used 
throughout the experiment (Section 2.8.2). Primary tumours from wild type (n=6), ApoE 
(n=5) and ApoE/ArKO (n=3) were stained for ER status. Cancer associated adipocytes in 
the tumours were analysed by using an antibody against perilipin, a protein that coats the 
adipocyte membrane (99). Perilipin optimization of antibody dilution was performed on 
EO771 tumours from the ApoE mice. The perilipin antibody dilutions used were 1:600, 
1:800 and 1:1000, where 1:800 was the optimum concentration used throughout the 
experiment (Section 2.8.2).  The proliferative status of the tumours was analysed by using 




cells undergoing mitosis (100). Histone-H3 is a core protein in the chromatin and its 10th 
and 28th serine residues get phosphorylated during mitosis (100). Antibody optimization 
was not performed with the pHH3 antibody as the concentration was used from an 
existing protocol (Section 2.8.2).  
 
4.3 Results 
4.3.1 Estrogen Receptor Status of EO771 Tumours 
When tumours were analysed for ER status using the ERα antibodies, all tumours stained 
negative regardless of mouse background (Figure 14). There was no staining observed in 
the nuclei of the tumour cells (Figure 14B). Tumours were stained alongside a positive 












Figure 14:  Representative ERα staining in human breast tumour and EO771 breast tumours in 
mice. 
Tumours were FFPE. Antigen retrieval was done using the pressure cooker method using citrate 
buffer. An antibody concentration of 1:100 was used. Staining was visualized using the AP red 
Chromogen by EnVision Kit. Representative ERα staining is shown at 5X (scale = 100 µm) for all 
the tumours. (A) ERα staining of human tumours. (B) Representative staining of ERα staining of 
EO771 tumours in wild type mice 
 
4.3.2 Cancer Associated Adipocytes in EO771 Tumours 
Tumour physiology of tumours grown in wild type, ApoE and ApoE/ArKO mice was 
studied. Intratumoral adipocytes, referred to as CAA, were examined by staining for 
perilipin. There were differences in the number of perilipin positive cells in the tumours 
from the three different mouse groups (examples of staining shown in Figure 15). 
Tumours from ApoE mice had significantly more perilipin positive cells (p<0.05) than wild 
type mice (Figure 16), with 1.03% ± 0.22% perilipin positive cells in tumours from ApoE 
mice, 0.34% ± 0.09% from wild type mice, and 0.57% ± 0.17% from ApoE/ArKO mice. 
Differences between tumours from ApoE and ApoE/ArKO, and wild type and ApoE/ArKO 








Figure 15: Representative CAA staining of perilipin in EO771 tumours in Wild Type, ApoE and 
ApoE/ArKO Mice.  
Tumours were FFPE. Antigen retrieval was done using the pressure cooker method using citrate 
buffer. An antibody concentration of 1:800 was used. Staining was visualized using the AP red 
Chromogen by EnVision Kit. The arrows indicate positive staining. Representative perilipin 
staining is shown at 5X (scale = 100 µm, left) and 40x (scale = 20 µm, right). (A) Perilipin staining 
of CAA in Wild Type tumours. (B) Perilipin staining of CAA in ApoE tumours. (C) Perilipin staining 








Figure 16: Percentage of perilipin positive cells in the tumours of wild type, ApoE and 
ApoE/ArKO mice. 
The graph shows data quantified from perilipin positive cells, which were calculated as a 
percentage of the average number of adipocytes per number of tumour cells from 20 random 
fields for wild type (n=9), ApoE (n=8) and ApoE/ArKO (n=7) mice. Data is represented as mean and 
standard error of mean. Data were analysed using 1way ANOVA followed by Newman-Keuls and 
Bonferroni multiple comparison tests. * P<0.05. 
  
 
4.3.3 Proliferation of EO771 Tumours 
Tumour physiology of wild type, ApoE and ApoE/ArKO was examined using pHH3 as a 
marker for cellular proliferation. Despite no difference in tumour growth rates at both 
the lag and log phase, there was a clear difference in cellular proliferation in the tumours 
of the wild type, ApoE and ApoE/ArKO mice as shown in Figure 17. The tumours of the 
ApoE/ArKO mice had the highest percentage of pHH3 positive cells whereas as the 
tumours of the wild type mice had the least pHH3 positive cells (Figure 18). 
 
  
































Figure 17: Representative mitotic staining of pHH3 in EO771 tumours in Wild Type, ApoE and 
ApoE/ArKO Mice 
Tumours were FFPE. Antigen retrieval was done using the pressure cooker method using citrate buffer. An 
Antibody concentration of 1:100 was used. Staining was visualized using the AP red Chromogen by EnVision 
Kit. The arrows indicate positive staining. Representative pHH3 staining is shown at 5X (scale = 100 µm, 
left) and 40x (scale = 20 µm, right). (A) pHH3 staining of mitotic cells in Wild Type tumours. (B) pHH3 









The tumours of the ApoE mice also had a significantly (p<0.05) greater percentage of 
pHH3 positive cells compared to tumours of the wild type mice 9. On average the 
tumours of the ApoE mice were stained more for pHH3 positive cells (2.31% ± 0.21%) 
compared to the tumours of the wild type mice which, were stained less (1.59% ± 
0.16%).  
 
There was a significant difference (p<0.05) between the percentage of pHH3 positive 
cells in the tumours of the ApoE and ApoE/ArKO mice. However this difference was 
smaller of approximately 0.9 % as compared to the difference between the tumours of 
ApoE/ArKO mice and wild type mice that was approximately 1.6%. On average the 
tumours of the ApoE mice were stained more for pHH3 positive cells (2.31% ± 0.21%) 






Figure 18: Representation of percentage of pHH3 positive cells in the tumours of wild type, 
ApoE and ApoE/ArKO mice 
The graph shows data quantified from pHH3 positive cells, which were calculated as a percentage 
of the average tumour cells from 20 random fields for wild type (n=8). ApoE (n=9) and ApoE/ArKO 
(n=6) mice. Data is represented as a standard error of mean. Data were analysed using 1way 

































The current study shows that EO771 tumours from wild type, ApoE and ApoE/ArKO mice 
stained negative for ER, suggesting that the EO771, a murine breast adenocarcinoma 
cell line, is ER-. Data in the literature are conflicting regarding the ER status of EO771 
tumours. Johnstone et al (101) is the only other study that has reported the EO771 cell 
line being ER-. Primary tumours from the EO771 were also PR, HER 2- and cytokeratin 5/6 
but were positive for epidermal growth factor receptor (EGFR) and mutant p53. They 
reported that EO771 cells have a triple negative and a basal-like phenotype. On the 
contrary various studies have reported the EO771 cells to be ER+ however, no data is 
available to confirm the validity of the EO771 cells being ER+ (102-104).  
 
An ER negative status of a tumour indicates that it does not respond to or require 
estrogen stimulation. Our study provides further evidence that the EO771 cell line is 
functionally ER negative, as ApoE/ArKO mice were able to form sizeable tumours. If the 
EO771 cell line is ER+ there would be no tumour growth observed in the ApoE/ArKO 
mice, as these mice lack aromatase activity. Aromatase is an enzyme involved in the 
conversion of androgens to estrogen (52). Adult aromatase deficient mice (ArKO) were 
shown to have no circulating estrogen (115).  
 
The ApoE mice had the highest number of intratumoral fat cells (CAA) compared to wild 
type and ApoE/ArKO mice. Zhang et al (105) have reported that excessive adipocyte 
signalling triggers increased adipocyte recruitment into the tumour. Intratumoral 
adipocytes may provide energy for cancer cell growth and proliferation via β-oxidation of 
fatty acids (105), as reported using human ovarian cancer cells in in vitro. Fatty acid β-
oxidation is a process that occurs in the mitochondria where free fatty acids (FFA) are 
broken down to Acetyl-CoA by fatty acyl CoA synthetase (FACS); (106). Acetyl CoA is used 
in the citric acid cycle to generate adenosine triphosphate (ATP); (106). The fact that the 
ApoE mice were the heaviest out the three groups indicates increased obesity and may 
explain why their tumours had more intratumoral fat compared to tumours from the wild 
type and ApoE/ArKO mice. However, our findings did not show a link between 
intratumoral adipocyte numbers and tumour growth as all mice from the three groups 





The mechanisms of how intratumoral fat cells may promote tumour growth and 
proliferation remain unresolved. Further studies with a larger sample size are required to 
explore the link between intratumoral fat and tumour growth and proliferation. 
 
Despite the ApoE mice having more intratumoral adipocytes, the tumours of the 
ApoE/ArKO mice were more proliferative compared to the ApoE mice, whereas the 
tumours from the wild type mice were less proliferative. The ApoE/ArKO phenotype 
might be contributing to aggressive tumour biology and more proliferative tumours, due 
to a higher inflammatory state, as reported by Scott et al (105). It is well documented 
that inflammation increases breast tumour proliferation by activation of various 
oncogenes (107-110). The phenotypic contribution to the proliferative status needs more 
research as the present study is the first and only study exploring the link between 







5 Analysis of Tumour Hypoxia  
5.1 Chapter Aim 
Hypoxia Inducible Factor 1 (HIF-1) is a dimeric transcription factor comprised of an alpha 
and beta subunit. HIF-1 plays an integral role in the body’s response at low oxygen 
concentrations, and is particularly important in tumours. HIF-1 regulates vascularization, 
immune response and anaerobic metabolism. The aim of this chapter was to determine 
the hypoxic status of the EO771 cell line and vivo tumours by analysing the protein levels 
of HIF 1α and pimonidazole staining. 
 
The experiments in this chapter were designed to determine: 
1. The expression level of HIF-1α in EO771 cells by western blot analysis 
2. The expression levels of HIF-1α in EO771 tumour lysates. 
3. Hypoxic state of tumours using pimonidazole staining. 
 
5.2 Experimental Design 
In vitro expression of HIF 1 was analysed by subjecting the EO771 cells to hypoxic 
conditions in the H35 hypoxia chamber (1% O2). Cobalt chloride (100 mM) was used as 
hypoxia mimetic. Glut 1 was investigated as one of the HIF-1 targets in vitro. Protein 
levels were determined using western blotting. Levels of -actin were as a control for 
normalising. A control experiment was also conducted where cells were grown under 
normoxic conditions (21% O2). 
 
In vivo levels of HIF-1 protein were determined using lysates from EO771 tumours 
grown in wild type, ApoE and ApoE/ArKO mice as well as internal metastases. Equal 




To assess tumour hypoxia mice were injected with pimonidazole (60 mg/kg). 
Pimonidazole was injected intraperitoneal 90 minutes prior to euthanasia. Pimonidazole 
is a good hypoxia marker as it binds to thiol adducts of macromolecules in hypoxic 
regions in FFPE sections using immunohistochemistry. Antibody optimization was not 
performed with the pimonidazole hypoxyprobe as the concentration was determined 
from an existing protocol. Two observers blinded to mouse genotype quantified staining, 
and data was presented as a H-Score. (Section 9.3) 
5.3 Results 
5.3.1 In vitro analysis of HIF-1α expression in EO771 Cells 
There was no significant difference observed in the expression of HIF-1α under normoxic 
or hypoxic in experiments using either cobalt chloride or 1% O2 (Figure 19 and Figure 20). 
No significant difference was also observed in the expression of GLUT-1 under normoxic 






Figure 19: Western blot of in vitro analysis of HIF-1α and GLUT-1 expression in EO771 cells 
under normoxic and hypoxic conditions 
EO771 cells were subject to hypoxic conditions by using a hypoxia chamber (1% O2) for 24 hours 
or 100 mM of cobalt chloride for 6 hours. Samples were loaded at 5 µg and 10 µg of protein. 
Protein levels of HIF-1α and GLUT-1 were analysed by western blotting. Expression of β-actin 
was used as loading control. 
5 µg protein 
  















Figure 20: Densitometry analysis of HIF-1α expression against β actin 
Densitometry analysis of HIF-1α protein levels compared to β-actin by western blot analysis under 
both normoxic and hypoxic conditions.  
 
 
5.3.2 In vivo analysis of HIF-1α expression in EO771 Tumours 
Primary EO771 tumours from ApoE/ArKO mice had significantly higher levels of HIF-1 
(p<0.05) than EO771 tumours from either wild type or ApoE mice (Figure 21 and Figure 
22). There was no significant difference observed in HIF-1α expression level between the 
ApoE and wild type mice (Figure 21 and Figure 22).  
 
 
5 µg protein 
10 µg protein 
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Figure 21: Representative example of western blot of in vivo HIF-1α expression in primary and 
secondary EO771 tumours from wild type, ApoE and ApoE/ArKO mice 
Tumour lysates for each mouse were analysed for HIF-1α expression level. 10 g of proteins was 
loaded per lane. -actin was used as the loading control. With 6 minutes exposure for HIF-1α and 
3 second exposure of -actin outcome of western blot for primary tumour lysate from wild type, 
ApoE and ApoE/ArKO mice 
 
 
Figure 22: Densitometry analysis of HIF-1α normalised to β-actin in primary tumours of wild 
type, ApoE and ApoE/ArKO mice 
Tumour HIF-1α levels were investigated in EO771 tumours grown in wild type (n=10), ApoE (n=10) 
and ApoE/ArKO (n=4) mice. After the tumour burden had reached approximately 200 mm3, mice 
were euthanized and tumours were harvested and homogenized. The homogenized tumour 
lysate was used to assess HIF-1α levels by Western blotting. Densitometry analysis of HIF-1α 
protein levels were normalised to β-actin. Data were analysed using 1way ANOVA followed by 
Newman-Keuls and Bonferroni multiple comparison tests. * P<0.05. 




























EO771 tumours that grew as internal metastases had increased levels of HIF-1α 
compared to primary tumours from the same mouse genotype (Figure 23). There was 
twice as much of HIF 1α (0.72  0.08) protein levels in the internal metastases compared 
to primary tumours (0.35  0.08) of the ApoE mice (p<0.05). The analysis of HIF-1α in the 
internal metastases of wild type mice was not completed due to time restrains.  
 
 
Figure 23: Densitometry analysis of HIF-1α normalised to -actin in primary tumours and 
internal metastases in ApoE mice 
Tumour HIF-1α levels were investigated in EO771 tumours grown in ApoE mice. Primary tumours 
(n= 10) and internal metastases (n=2) were compared. Tumours were harvested and 
homogenized and tumour lysate was used to assess HIF-1α levels by Western blotting. 
Densitometry analysis of HIF-1α protein levels were normalised to β-actin. Data were analysed 































5.3.3 Immunohistochemical analysis of Hypoxia Status of EO771 Tumours 
Pimonidazole provides a marker for hypoxic regions within the tumour (Figure 24 and 
Figure 25). Wild type (n=5), ApoE (n=5) and ApoE/ArKO (n=4) mice tumours were 
assessed for hypoxia by quantification of pimonidazole staining based on area and 









Figure 24: Representative hypoxia staining of pimonidazole in EO771 primary tumours in Wild 
Type, ApoE and ApoE/ArKO Mice 
Tumours were FFPE. Antigen retrieval was done using the pressure cooker method using citrate 
buffer. An Antibody concentration of 1:1000 was used. Staining was visualized using the AP red 
Chromogen by EnVision Kit. Arrows indicate positive staining. Representative pimonidazole 
staining is shown at 5X (scale = 100 µm, left) and 40x (scale = 20 µm, right). (A) Pimonidazole 
staining of hypoxic regions in Wild Type tumours. (B) Pimonidazole staining of hypoxic region in 











Figure 25: Representative hypoxia staining of pimonidazole in EO771 internal metastasis in 
ApoE mice 
Tumours were FFPE. Antigen retrieval was done using the pressure cooker method using citrate 
buffer. An Antibody concentration of 1:1000 was used. Staining was visualized using the AP red 
Chromogen by EnVision Kit.  Representative pimonidazole staining is shown at 5X (scale = 100 




There was no significant difference (p=0.545) between the pimonidazole staining in the 
primary tumours of the wild type, ApoE and ApoE/ArKO mice (Figure 26). However 
internal metastases of ApoE mice showed a significance increase (p<0.0001) in 
pimonidazole staining compared to all primary tumours. 
 
The primary tumour of the ApoE/ArKO mice stained slightly stronger (37.50 ± 19.63) than 
the ApoE mice (22.80 ± 9.79) and wild type mice (17.80 ± 6.151). However the difference 








Figure 26: Representation of percentage of tumour hypoxia and intensity of staining (H Score) 
of pimonidazole in the tumours of wild type, ApoE and ApoE/ArKO mice and internal 
metastasis. 
The graph shows data quantified from whole tumour analysis where the percentage of 
pimonidazole staining was multiplied by the intensity of staining (H Score) for wild type (n=5). 
ApoE (n=5) and ApoE/ArKO (n=4) mice and internal metastasis (n=2) Data is represented as a 
standard error of mean. Data were analysed using 1way ANOVA followed by Newman-Keuls and 
Bonferroni multiple comparison tests. 
 
5.4 Discussion 
HIF-1 has been shown to play an important role in tumour pathology increasing 
vascularization and metabolism (116). This supports tumour survival, proliferation and 
invasion. The current study shows that HIF-1 in EO771 cells has high basal HIF-1 levels 
under normoxic conditions. This implicates that HIF-1 in EO771 cells is constitutively 
expressed under both normoxic and hypoxic conditions. Sceneay et al (117) also reported 
that HIF-1 was constitutively expressed in both normoxic and hypoxic conditions. 
However, Sceneay et al (117) showed that there was an increased expression of HIF-1 
under hypoxic conditions compared to normoxic conditions. This was not the case 
observed in the current studies as, there was no significant difference observed in HIF-1 
expression (section 5.3.1). The only difference between these studies was that Sceneay et 
al (117) exposed the EO771 cells for 2 hours under hypoxic conditions (2% oxygen 
concentration) where as in the current study the EO771 cells were exposed to 24 hours 
under hypoxic conditions (1% O2). It has been reported that confluency can induce HIF-1 


















levels in certain cell types (118). After 24 hours, EO771 cells could be over confluent and 
this could enhance HIF-1 under normoxic conditions. Due to time restrains the 
experiment was not carried out at under the same experimental conditions as the study 
done by Sceneay et al (117).  
 
The current study is the first study to investigate the HIF-1 levels in EO771 tumours 
grown in mice. The primary tumours of the ApoE/ArKO mice were more hypoxic than 
primary tumours from wild type and ApoE mice. The primary tumours from ApoE/ArKO 
mice had the highest level of HIF-1 and pimonidazole staining compared to the primary 
tumours of wild type and ApoE mice (Figure 23 and 26). A positive relationship of HIF-1 
levels and pimonidazole staining was only evident in internal metastases (Figure 27). 
There was no relationship observed between HIF-1 and pimonidazole staining in 




Figure 27: Data showing relationship between pimonidazole staining and HIF-1α levels in 
EO771 primary tumours and internal metastases.  
The graph shows the relationship between pimonidazole staining and HIF-1α levels in primary 
tumours from wild type (n=5), ApoE (n=5) and ApoE/ArKO (n=4) mice. Data from internal 
metastases from ApoE mice (n=2) is also shown. 
 
 
It has been reported that HIF-1 is involved in tumour growth and survival (119). HIF-1 




transcription and translation of angiogenic factors (119). The role of HIF-1 in 
angiogenesis will be further explored in correlation to VEGF, an angiogenesis protein, in 
chapter 6. The role of HIF-1 in altering the metabolism of tumour cells to adapt to low 
oxygen levels by increasing glucose transporters and glycolysis (116, 119) was not 
analysed in EO771 tumours in mice. HIF-1 has also been reported to shift the balance 
between pro apoptotic and anti-apoptotic effects hence decreasing apoptosis of tumour 
cells and increasing their survival (119). The current study does not show the role of HIF-
1 in pro and anti-apoptotic effects. Nonetheless, the data from pHH3 staining supports 
the role of HIF-1 in increasing tumour survival as tumours from ApoE/ArKO mice had 
higher levels of HIF-1 and were more proliferative compared to tumours from wild type 
and ApoE mice.  
 
HIF-1 has also been shown to activate other oncogenes that further promote tumour 
growth and proliferation (116). Cancer studies with mouse models have also reported 
that HIF-1 increases lung, colorectal, renal and prostate cancer growth and angiogenesis 
(120, 121, 122). The current study shows that internal metastases are more hypoxic than 
primary tumours. This was evident as both HIF-1 levels and pimonidazole staining was 
significantly higher in internal metastasis compared to primary EO771 tumours from 
ApoE mice (Figure 23 and 26).  
 
Studies have reported that HIF-1 increases distant metastasis. However, this was not 
the case observed in the present study as primary tumours from ApoE/ArKO mice had 
high levels of HIF-1 but there were no distant metastases observed in this group of 
mice. The likely reason for the tumours in the ApoE/ArKO mice not undergoing 
metastases might be due to an increased expression of metastasis suppressor genes 
(MSGs). It has been reported that MSGs prevent distant metastasis but do not affect the 
growth of primary tumours (123). The other likely reason for this phenomenon could be 
an immune response that is preventing distant metastases in the ApoE/ArKO mice. There 
is no evidence in the literature as to whether the MSGs outweigh the effect of HIF-1 and 
prevent distant metastases. The mechanisms associated with preventing distant 
metastases in ApoE/ArKO mice despite aggressive tumour biology remain unclear and 





6 Analysis of Adipokine using an Adipokine 
Array and ELISA 
6.1 Chapter Aims 
The aim of this chapter was to analyse adipokines in tumours and plasma of the wild 
type, ApoE and ApoE/ArKO mice. We were also interested in determining the difference 
in adipokines between the primary tumours and internal metastases. 
The experiments in this chapter were designed: 
1. To determine differences in adipokine levels between EO771 from wild type, ApoE 
and ApoE/ArKO mice by using a mouse adipokine array. 
2. To compare adipokine levels between primary tumours and internal metastases. 
3. To measure levels of VEGF and IGFBP5 in tumours and plasma samples from wild 
type, ApoE and ApoE/ArKO mice by ELISA. 
6.2 Experimental Design 
A mouse obesity adipokine antibody array was used to determine the expression levels of 
different adipokines in tumour lysates. Four candidates were chosen from each group 
(wild type, ApoE and ApoE/ArKO mice) with the largest primary tumour and no internal 
metastases. For internal metastases only two samples from the ApoE mice were 
available. For each membrane 100 µg of protein from 4 different tumours were combined 
together to give a final protein ample of 400 µg. For the internal metastases 200 µg from 
each sample were combined together to give a final protein sample of 400 µg. The 
adipokine array was quantified by densitometry analysis.   
 
VEGF is a protein that stimulates vascularization and angiogenesis. IGFBP5 is a protein 
that is involved in controlling cell growth and metabolism. Protein concentrations of VEGF 
and IGFBP5 in both primary tumours and internal metastases of the wild type, ApoE and 




the IGFBP5 ELISA, tumour lysates were diluted 20 fold and plasma was diluted 500 fold. 
For the VEGF ELISA, tumour lysate was diluted 25 fold and plasma was diluted 100 fold 
BCA Assay was used to quantify the amount of protein in each tumour lysate (Section 
2.5.1). Absorbance of each tumour lysate sample for both the VEGF and IGFBP5 ELISA was 
standardised to the amount of protein in each sample. 
 
6.3 Results 
6.3.1 Adipokine Antibody Array 
The membranes from the mouse adipokine array are presented in Figure 28 .The layout 
and coordinates of the target proteins are shown in Section 9.4. Densitometry analysis 
detected 23 proteins out of 38 proteins that could be detected by the array (Section 9.4, 







Figure 28: Mouse adipokine antibody array 
Ten minute exposure outcome of the mouse adipokine proteome profiler for (A) primary tumour 
lysate from wild type mice, (B) primary tumour lysates from ApoE mice, (C) primary tumour 
lysates from ApoE/ArKO mice and (D) internal metastases from ApoE mice. Four candidates were 
chosen from each group (wild type, ApoE and ApoE/ArKO mice) with the largest primary tumour 
and no internal metastases. For internal metastases only two samples from the ApoE mice were 
available. For each membrane 100 µg of protein from 4 different tumours were combined 



















The mean pixel density of each protein was standardised to the corresponding protein 
relative to mean density of the wild type protein (Figure 29). There were 14 proteins that 
changed more than 25% relative to corresponding the mean pixel density of the wild type 
protein (Figure 29). IGFBP5 and VEGF were highly expressed in the primary tumours of 
the ApoE/ArKO mice compared with internal metastases and tumours to the wild type 
and ApoE mice. Around 7 proteins were highly expressed in the internal metastases 








Figure 29: Relative protein levels in tumour lysates 
Protein levels were standardised to those detected in primary tumours of wild type mice, and 14 proteins changed by more than 25% relative to the expression 
levels of proteins in the primary tumours of the wild type mice. VEGF and IGFBP5 were increased in the primary tumours of the ApoE/ArKO mice. More than 

























6.3.2 Insulin-like Growth Factor Binding Protein 5 ELISA 
The IGFBP5 protein levels detected by mouse IGFBP5 ELISA were standardized to the 
total protein levels in tumour lysates as determined by BCA Assay (Section 2.5.1). Primary 
tumours from EO771 tumours of ApoE/ArKO mice had a significantly lower concentration 
of IGFBP5 (p<0.01) than EO771 tumours from either wild type or ApoE mice (Figure 30). 
ApoE mice had also lower levels of IGFBP5 protein concentrations (p<0.05) than wild type 
mice (Figure 30).  
 
 
Figure 30: Mouse IGFBP5 ELISA for primary tumour and internal metastasis lysates from wild 
type, ApoE and ApoE/ArKO mice 
The graph shows the IGFBP5 protein concentration detected by Mouse ELISA kit. The IGFBP5 
concentration was standardized to protein levels in the tumour lysate. IGFBP5 was analysed in 
primary tumour lysates of wild type (n=9), ApoE (n=8) and ApoE/ArKO (n=6) mice. IGFBP5 
concentrations was also analysed from lysates of Internal metastasis of wild type (n=3) and ApoE 
(n=3) mice were also analysed. Data were analysed using 1way ANOVA followed by Newman-
Keuls and Bonferroni multiple comparison tests. * p<0.05, ** p<0.01, *** p<0.001. 
 
 
EO771 tumours that grew as internal metastases in wild type mice had a significantly 
lower IGFBP5 protein level (p<0.001) than primary tumours in these mice. The difference 
between primary tumours an internal metastases of wild type mice is 85%. There was no 
significant difference in IGFBP5 protein levels between primary tumours and internal 



































The plasma from ApoE/ArKO mice bearing primary tumours had the lowest 
concentrations of IGFBP5 compared to wild type and ApoE mice bearing primary 
tumours. However, the difference was not statistically significant (Figure 31). Data from 
ELISA analysis of IGFBP5 also showed an elevated protein concentration of IGFBP5 in mice 
bearing internal metastases compared to primary tumours but the difference was not 
statistically significant. Overall there was no significant difference in IGFBP5 protein level 
in plasma from wild type, ApoE and ApoE/ArKO mice bearing primary tumours or internal 




Figure 31: Mouse IGFBP5 ELISA for plasma from wild type, ApoE and ApoE/ArKO mice 
The graph shows the IGFBP5 protein concentration in plasma detected by Mouse ELISA kit in wild 
type (n=9), ApoE (n=8) and ApoE/ArKO (n=8) mice. Plasma of wild type (n=3) and ApoE (n=3) mice 
bearing internal metastasis were grouped separately. Data were analysed using 1way ANOVA 
followed by Newman-Keuls and Bonferroni multiple comparison tests. 
 
6.3.3 Vascular Endothelial Growth Factor ELISA 
Primary EO771 tumours in ApoE/ArKO mice had a higher concentrations of VEGF 
compared to wild type and ApoE mice (Figure 32) but this did not reach significance. 
Primary tumours from ApoE/ArKO mice trended to have 48% more VEGF protein 
concentration than ApoE and 54% more than wild type.  
 
Internal metastases of ApoE mice had more VEGF concentration compared to wild type 
































metastases had more VEGF protein concentration compared to primary tumours from 
both wild type and ApoE mice, but due to large variability between samples the 




Figure 32: VEGF ELISA for primary and internal metastasis tumour lysates from wild type, 
ApoE and ApoE/ArKO mice 
The graph shows the tumour VEGF protein concentration detected by Mouse ELISA kit. The VEGF 
expression level was standardized to protein levels in the tumour lysate detected by BCA Assay. 
VEGF was analysed in primary tumour lysates of wild type (n=8), ApoE (n=6) and ApoE/ArKO (n=6) 
mice. Internal metastasis of wild type (n=3) and ApoE (n=3) mice were also analysed. Data were 




There was no significant difference in the VEGF protein concentrations of plasma from 
wild type, ApoE and ApoE/ArKO mice with only primary tumour burden (Figure 33). 
Plasma VEGF levels were significantly higher in wild type mice with internal metastases 
(p<0.01) but not in ApoE mice with internal metastases (Figure 33). The VEGF protein 
concentration in plasma from wild type mice with internal metastases was significantly 
































Figure 33: VEGF ELISA for plasma from wild type, ApoE and ApoE/ArKO mice 
The graph shows the plasma VEGF protein concentration detected by Mouse ELISA kit (R&D) in 
wild type (n=11), ApoE (n=7) and ApoE/ArKO (n=8) mice. Plasma of wild type (n=3) and ApoE 
(n=3) that had internal metastasis were also grouped separately. Data were analysed using 1way 
ANOVA followed by Newman-Keuls and Bonferroni multiple comparison tests. *p<0.05, **p<0.01. 
 
 
Data was analysed using logarithmic analysis as opposed to 4-parameter logistic curve as 
suggested by the manufacturers (R&D Systems). The 4 parameter logistic curve was not 
used as concentration of tumour lysates were not within the range of the standard curve. 
Therefore, no data was obtained for analysis of some of the samples, especially data for 
tumour lysates.  
 
6.4 Discussion 
VEGF is a protein involved in promoting sprouting of endothelial cells to create new 
vasculature which is termed as angiogenesis (124). It is well documented from murine 
breast cancer models that VEGF supports tumour pathology (3, 50, 51, 103, 124, 125). 
VEGF increases tumour invasion and distant metastasis by aggravating intratumoural 
hypoxia and creating a pro-tumoural microenvironment (125). The present study shows 
elevated tumour VEGF levels in ApoE/ArKO mice causing aggressive tumour biology. It is 
well documented that VEGF contributes to breast cancer progression through paracrine 
(angiogenesis) and autocrine (migration and proliferation) signalling leading to aggressive 
tumour biology (51). The current data supports that VEGF also supports distant 
metastasis as both internal metastases from ApoE and wild type mice had elevated levels 
































VEGF concentrations were associated with high levels of HIF-1 protein in internal 
metastases, however there was no relationship observed between HIF-1 protein levels 
and tumour VEGF concentrations in mice with in primary tumour burden (Figure 34). 
 
Figure 34: Data showing relationship between tumour VEGF concentrations and HIF-1α levels 
in EO771 primary tumours and internal metastases. 
The graph shows the relationship between tumour VEGF concentrations and HIF-1α levels in 
primary tumours from wild type (n=7), ApoE (n=5) and ApoE/ArKO (n=4) mice. Data from internal 
metastases from ApoE mice (n=2) is also shown. Data were analysed using Pearson’s correlation 
statistical test. P<0.001 
 
Previous studies have reported the role of plasma VEGF in clinicopathological features 
and its positive correlation with tumour VEGF levels (50, 124). However the current study 
does not show any relationship between plasma and tumour VEGF levels (Figure 35). 































Figure 35: Data showing relationship between tumour and plasma VEGF concentrations in 
EO771 primary tumours and internal metastases 
The graph shows the relationship between plasma and tumour VEGF concentrations for mice with 
primary tumour burden: wild type (n=8), ApoE (n=6) and ApoE/ArKO (n=6) mice. Data from 
internal metastases from wild type (n=2) and ApoE mice (n=2) is also shown. Data were analysed 
using Pearson’s correlation statistical test. 
 
Insulin-like growth factor binding proteins (IGFBPs) either increase or decrease the 
actions of IGFs that play an important role in controlling cell proliferation, differentiation 
and apoptosis (126). In particular increased levels of IGF-1 have been noted to decrease 
the action of IGFBP3 and IGFBP5 increasing the risk of breast, lung, colorectal and 
prostate cancer. Although the results from the ELISA assay and cytokine array are 
contradicting, the ELISA assay is a much better quantitative analysis of IGFBP5 compared 
to the adipokine array (127). Decreased levels of IGFBPs are associated with breast 
tumour proliferation in ApoE/ArKO mice. Tumour and plasma IGFBP5 concentrations 
were correlated (p<0.05) in ApoE (R square = 0.77) and ApoE/ArKO (R square = 0.67) mice 
with primary tumour burden (Figure 36). There was no relationship between tumour and 
plasma IGFBP5 concentrations in wild type mice with either primary of internal 
metastases and ApoE mice with internal metastases (Figure 36). 
































Figure 36: Data showing relationship between tumour and plasma IGFBP5 concentrations in 
EO771 primary tumours and internal metastases 
The graph shows the relationship between plasma and tumour IGFBP5 concentration from wild 
type (n=8), ApoE (n=6) and ApoE/ArKO (n=6) mice. Data from internal metastases from wild type 
(n=3) and ApoE mice (n=2) is also shown. There was a positive correlation between primary 
tumours from ApoE (R square = 0.77) and ApoE/ArKO mice (R square = 0.67). Data were analysed 
using Pearson’s correlation statistical test. P<0.05  
 
 
The VEGF ELISA data for tumours follows a similar trend to adipokine array data, but 
IGFBP5 does not. Hence the data from adipokine array should be viewed with caution 
and requires further validation (p<0.05). 
It is well documented that adipokines and inflammation have been mechanistically linked 
to promote tumour pathology (58, 61, 128, 129). The present study documents a wide 
range of adipokines that may be associated with tumour growth, proliferation and 
invasion. The role of adipokines detected by a mouse adipokine array in primary tumours 
of wild type, ApoE and ApoE/ArKO mice along with internal metastasis from ApoE mice is 
described in Section 9.4 (Table 12). 
 
The current study shows that internal metastases contribute to a higher inflammatory 
state than the primary tumours. CRP, TIMP1, pentraxin and endocan are biomarkers of 
inflammation during cancer development. TIMP1 in mouse xenografts studies has been 
reported to indirectly support breast tumour metastases (130). Its direct role in tumour 
invasion has not been clearly understood (130). Only one preliminary study has been 
conducted to explore the role of mouse endocan (131). The study reported that mouse 































endocan has a similar function as human endocan in causing a poor prognosis for breast 
cancer (131). However there is no data in the literature to confirm the role of pentraxin in 
tumour pathology in animal models of breast cancer. The primary tumours of the ApoE 
and wild type mice had elevated levels of TIMP1, endocan and pentraxin compared to the 
primary tumours of the ApoE/ArKO mice. This could explain the likely reason for these 
tumours to have metastasised in these two models but not in the ApoE/ArKO mice.  
CRP is a marker of inflammation that is linked with breast cancer risk (132) Only one 
study has reported the role of CRP in tumour growth and invasion via Sphingosome -1-
phosphate (S1P) mediated inflammation (133). S1P is an inflammation mediator that 
elevats CRP formation (133). Elevated levels of CRP promote distant metastases, however 
the understanding of the role of CRP in breast tumour invasion is limited (133). The 
current study shows an elevated level of CRP in tumours of the wild type mice compared 
to ApoE/ArKO mice. Scott et al (105) reported a higher level of CRP in the plasma of the 
ApoE/ArKO mice than wild type mice. However, there is no clear evidence as to whether 
the role of CRP in plasma (systemic effect) and tumours (microenvironment) are 
associated. 
RANTES and M-CSF support tumour growth, proliferation and invasion by recruiting the 
immune cells into the tumour (134, 135). RANTES promotes tumour invasion by 
recruiting macrophages into the tumours causing distant metastasis. On the other hand, 
Mevan et al (136) reported that RANTES in metastatic and non-metastatic syngeneic 
mouse tumour models does not support tumour pathology. M-CSF initiates distant 
metastases by changing TAMs to a pro-tumourigenic phenotype (134, 137). High levels of 
RANTES and M-CSF explain the development of internal metastases in tumour bearing 
wild type mice. However, the reason as to why the tumour bearing ApoE mice had low 
levels of RANTES and M-CSF despite developing internal metastases remains unclear.  
Interestingly, resistin, a protein that is linked with heart diseases and atherosclerosis was 
higher in primary tumours of wild type mice compared to ApoE and ApoE/ArKO mice. 
This was highly unexpected as the both the ApoE and ApoE/ArKO mice models are highly 
susceptible to heart diseases and atherosclerosis and are a model widely used in heart 
disease research. Resistin has also been reported to support tumour growth by increasing 




Overall the results from the adipokine array exhibit an increase inflammatory state in the 
internal metastases compared to primary tumours. However there is no clear 
understanding as to why the tumours from ApoE/ArKO mice had lower levels of 
inflammatory adipokines such as endocan and CRP than wild type mice despite its higher 
inflammatory phenotypic trait. The tumours from the ApoE/ArKO mice were more 
proliferative due to an increased tumour VEGF levels and decreased tumour and plasma 








7.1 Summary of Findings 
Human epidemiological studies have identified metabolic syndrome as a risk factor for 
breast cancer. The aim of the current study was to investigate the role of metabolic 
syndrome especially obesity in the risk associated with an aggressive tumour biology 
using ApoE and ApoE/ArKO obese mouse models of breast cancer. In the present study 
neither ApoE nor ApoE/ArKO mice were obese compared to the wild type mice. All three 
groups of mice had a similar tumour growth rate, although it appears that older ApoE 
mice had a longer tumour latency period. Internal metastases were observed in ApoE and 
wild type mice but not ApoE/ArKO mice.  
 
The tumours from the ApoE mice had the highest number of intratumoural fat cells. The 
tumours from ApoE/ArKO mice were highly proliferative. Tumours from ApoE/ArKO mice 
had increased levels of HIF-1 and VEGF and decreased level of IGFBP5. Increased levels 
of HIF-1 and VEGF and decreased level of IGFBP5 have been reported to support the 
tumour pathology and proliferation that causes aggressive tumour biology. 
 
The tumours from ApoE/ArKO mice had low levels of inflammatory adipokines such as M-
CSF, CRP and endocan than tumours from wild type mice. This was unexpected as 
inflammation is a phenotypic trait for the ApoE/ArKO mice. The current observation is 
limited by the quantitative ability of the adipokine array The current study demonstrated 






This is the first study to investigate the link between metabolic syndrome in a mouse 
model. The current study shows that metabolic syndrome is associated with an 
aggressive breast tumour phenotype. 
7.2 Future Work 
The current research is ongoing with increased number of wild type, ApoE and 
ApoE/ArKO mice and tumours continuing to be analysed as described in this thesis.  
 
The current study did not explore vascularization by immunohistochemistry staining of 
CD-31, a protein that stains blood vessels. Further studies are required to analyse the 
inflammatory status of the ApoE/ArKO mice before and after tumour burden. A more 
quantitative analysis such as ELISA would give a better quantification of additional 
adipokines and cytokines as opposed to an antibody array, which is semi-quantitative. 
The role of CRP, endocan and M-CSF needs to be further validated with breast cancer 
initiation and progression in the metabolic syndrome mouse model.  
 
Furthermore, it would be interesting to explore how ER+ cell line such as 67-NR affects 
breast tumour initiation and growth in a metabolic syndrome mouse model. This would 
give an insight as to whether aggressive tumour biology is dependent or independent of 
ER status in a metabolic mouse model of breast cancer. Future research should focus on 
using obese ApoE/ArKO and ApoE mice potentially using a high fat diet. This will provide a 
clear link between metabolic syndrome associated obesity and breast cancer risk.  
 
Future work should explore the response of tumour bearing ApoE/ArKO mice to 
chemotherapy and will give a better understanding of drug metabolism. This is because in 









Increasing reports are providing the association between metabolic syndrome and breast 
cancer risk. However, more research is needed to accurately elucidate breast tumour 
characteristics and behaviour associated with metabolic syndrome. 
 
This is the first study to investigate breast cancer in ApoE/ArKO metabolic syndrome 
mouse model. This is also the first study to investigate breast cancer in non-obese ApoE 
mice. The results show that mouse model of metabolic syndrome has aggressive tumour 
biology supported by increase hypoxia, vascularization, angiogenesis and proliferation.  
 
The ApoE/ArKO mouse model represents a valuable tool for research that will bridge the 
gap between cell culture models and breast cancer patients. Future work is required to 







8 Supplementary Data 
8.1 Methods 
8.2 Mouse Adipose Tissue Culture 
8.2.1 Adipose Tissue Co-culture with EO771 cells. 
Omental fat collected from ApoE and ApoE/ArKO mice were cut into small section of 2 
mm and plated in a Corning Cell BIND 12 well plate with 2 mL of DMEM/F12 (DMEM with 
10% fetal calf serum (FCS) and 1% antibiotic-antimycotic  (Thermofisher)). The adipose 
tissue was maintained in media for three days and media changed daily. After 3 days, 
1x105 EO771 cells were added to the fat and co-cultured for 3 days. After the 3 day co-
culture the fat was collected and formalin fixed and paraffin embedded for 
immunohistochemistry analysis. 
 
8.2.2 Preadipocyte Isolation and Adipogenesis 
Omental fat collected from mice was minced and enzymatically digested using a 2 mg/mL 
solution of Collagenase 1 in Hanks balanced salt solution (HBSS) and, 1 mL of  
Collagenase solution was added to 0.1 g of minced fat and incubated for 1 hour in a water 
bath at 37°C. The contents were shaken after every 15 minutes. After 1 hour incubation, 
the contents were passed through a fine tissue sieve (250 µm) and centrifuged for 10 
minutes at 500 x g.  
 
The top layer of mature adipocytes was collected and frozen down to -80°C. The 
supernatant was discarded, and the pellet containing preadipocytes and red blood cells 
was resuspended in 5 mL of DMEM/F12 media and passed through a 70 µm filter. The 




pellet was resuspended in 2 mL of DMEM/F12 media. After resuspension, 1 mL of 
preadipocyte enriched suspension was added to each well of a 12 well Cell BIND plate 
(Corning; In Vitro Technologies). Media was changed every other day until cells reached 
confluency. Induction media (Table 8) was added after 12 days after cells reached 
confluency. After 48 hours induction media was replaced with maintenance media (Table 
9). Maintenance media was replaced every other day for 10 days after oil droplets 
become obvious. 
 
Table 8: Induction Media 
Reagent Concentration Volume for 10 mL Source 
Insulin 10 µg/mL 1 µL Sigma 
IBMX 1 µm 1 µL Sapphire Bioscience 
Dexamethasone 0.5 mM 200 µL Sapphire Bioscience 
DMEM/F12  9.798 mL Thermofisher 
 
Table 9: Maintenance Media 
Reagent Concentration Volume for 10 mL Source 
Insulin 0.1 µg/mL 1 µL Sigma 
DMEM/F12  9.999 mL Thermofisher 
 
8.2.3 EO771 Cells and Adipocyte Co-Culture 
EO771 cells were seeded at a density of 5x104 cells in an insert that was placed on top of 
the plate containing the matured adipocytes. The inserts are perforates that allows an 
exchange of media between the EO771 cells and adipocytes. The EO771 cells and 
adipocytes were co cultured for 3 days. After a co culture the EO771 cells were 
trypsinized and reseeded into a 24 well plated and left for 12 hours in an incubator for 
cell attachment. After 12 hours, each well was scratched using the tip of a yellow pipette 
to analyse the rate of cell migration between EO771 cells co-cultured with adipocytes and 






8.3 Results and Discussion 
From immunohistochemistry analysis, there was no difference observed in adipocyte 
morphology between adipose tissue co-cultured with EO771 cells and adipose tissue 
grown in absence of EO771 cells. There was no significant difference observed between 
the motility of the co-cultured EO771 cells and the EO771 cells grown in absence of 
adipocytes (Figure 37). The current study shows the preliminary results of the co-culture 
of mouse adipocytes and EO771 cells which can be explored further to understand the 







Figure 37: Migration assay of EO771 cells co-cultured with adipocytes and EO771 cultured 
without adipocytes 
The figure above is a representation of migration/scratch assay of EO771 cells grown in 
presence or absence of mouse adipocytes. The migration was monitored at the time 











9.1 Buffers  
9.1.1 Phosphate Buffered Saline (PBS) 10x 
Dissolving 5 tablets of PBS in 1 L of MilliQ water made PBS 10x. Each tablet of PBS 
contains: 0.01M Phosphate buffer, 0.0027M Potassium Chloride, 0.137M Sodium 
Chloride, pH 7.4 (Sigma Aldrich)  
 
Mixing 100 mL of PBS 10x and 900 mL of MilliQ water made PBS 1x. 
 
9.1.2 PBS x 1 Plus 0.05% Tween 20 
PBS-T was made by adding 0.05% (v/v) of Tween 20 (Sigma) to 1 L of PBS 1x. 
 
9.1.3 Citrate Buffer for Antigen Retrieval 
Citrate buffer was made by preparing a 10 mM solution of trisodium citrate dihydrate 
(Sigma Aldrich) at pH6 followed by 0.05% (v/v) Tween 20 (Sigma). 
 
9.1.4 RIPA Buffer for Tumour and Cell Lysis 
RIPA buffer for tumour and cell lysis was made as shown in Table 10.  
0.1M Dithiothreitol (DTT); (Sigma) and 1x Protease Inhibitor Cocktail used according to 








Table 10: Reagents used to make RIPA lysis buffer 
Stock Manufacturer Volume [Final] 
5 M NaCl Fisher Scientific 3 mL 150 mM 
1 M Tris, pH 8.0 Sigma 5 mL 50 mM 
10% NP-40 (IGEPAL CA-630) Sigma 10 mL 1.0% 
10% sodium deoxycholate Sigma 5 mL 0.5% 
10% SDS Sigma 1 mL 0.1% 




9.1.5 Tris Buffered Saline (TBS)  
TBS 10x was made by dissolving 24.2 g of tris base and 80g of sodium chloride in 1 L of 
MilliQ water.  
 
TBS-T 1x was made by mixing 100 mL of TBS 10x and 900 mL of MilliQ water and added 
0.1% (v/v) Tween 20. 
9.1.6 Stripping Buffer 
Stripping buffer was prepared by adding 200 mM glycine (Sigma Aldrich) and 3.5 mM SDS 





9.2 Estimation of Tumour Volume Based On a Modified 
Ellipsoidal Formula 
 
In order to determine tumour volume by calliper measurement, the greatest longitudinal 
diameter (length) and the greatest transverse diameter (width) was determined. Tumour 






























9.3 Quantification of Pimonidazole staining in EO771 tumours 
 
Pimonidazole staining was semi quantified by using a modified H-score, which takes into 
account the intensity of staining intensity as well as the percentage of cells with positive 
staining.  
 
The H-score is given as the sum of the percentage of staining multiplied by an ordinal 
value corresponding to the intensity level (1 = weak, 2 = moderate, 3 = strong) where, 
 
H-Score = (% at 0) * 0 + (% at 1) * 1 + (% at 2) * 2 + (% at 3) * 3.  
 
Thus, this score produces a continuous variable that ranges from 0 (no staining in 
tumour) to 300 (intense staining of tumour). Representative staining intensity is shown in 
Figure 38.  
 
Two independent observers (Anishah Mandani and Gabi Dachs), in a blinded manner, 








Figure 38: Representative intensity of pimonidazole staining 
The H-score is given as the sum of the percentage of staining multiplied by an ordinal value 
corresponding to the intensity level (1 = weak, 2 = moderate, 3 = strong), where H-Score = (% at 
0) * 0 + (% at 1) * 1 + (% at 2) * 2 + (% at 3) * 3. Thus, this score produces a continuous variable 
that ranges from 0 (no staining in tumour) to 300 (intense staining of tumour). 
  
Weak staining 
Score = 1 
 
Moderate staining 
Score = 2 
 
Strong staining 





9.4 Mouse Adipokine Array Coordinates 
Mouse obesity adipokine array kit (R&D systems) was used to analyse the presence of 
different adipokines present in tumour lysate samples. The layout of adipokines that are 
detected by the obesity array is shown in Figure 39 and the protein represented by each 





Figure 39: Mouse adipokine array coordinates 














Figure 40: Relative pixel density of detected proteins by the adipokine antibody array 
Twenty three out of 38 proteins were differentially expressed using the mouse adipokine antibody array. Data was analysed by denistmetry analysis where the 
mean of 2 spots of each protein was normalised to the mean the 3 reference spots. Four candidates were chosen from each group (wild type, ApoE and 
ApoE/ArKO mice) with the largest tumour and no internal metastases. For internal metastases only two samples from the ApoE mice were available. For each 
























Table 12: The role and function of the adipokines detected by the mouse adipokine array in 
primary and secondary tumours of wild type, ApoE and ApoE/ArKO mice 
Adipokine  Function and role  
VEGF Increases tissue vascularisation (angiogenesis) (50, 51, 58) 
MCP1 Regulates migration and infiltration of macrophages (139) 
M-CSF Involved in proliferation, differentiation and survival of macrophages 
(140) 
Pentraxin 2 & 3 Multimeric structures that are regulated in response to inflammation 
(141) 
RANTES Recruits tumour associated macrophages to tumour sites (142) 
RBP4 Associated with insulin resistance (128) 
Resistin Increases in presence of pro-inflammatory cytokines and associated with 
heart diseases (143) 
Serpin E1 Risk factor for atherosclerosis and in blood clot degradation (144) 
TIMP1 Metalloproteinases inhibitor and promotes cell proliferation (145) 
IGFBP 1, 2, 3, 5 & 
6 
Binding proteins for IGFs (126) 
Lipocalin Involved in immune response mediated inflammation (104) 
Adiponectin Regulates fatty acid break down and glucose levels (79, 84, 87, 90) 
CRP Protein released in an inflammatory state (132) 
DPPIV Involved in glucose metabolism (146) 
Endocan Elevated during angiogenesis and inflammation (147, 148) 
Fetuin A Down regulates insulin signalling pathway (149) 
FGF Acidic Involved in endocrine signalling and angiogenesis (150) 






9.5 .VEGF ELISA Raw Data Analysis by Logarithmic and 4 
Parameter Logistic Standard Curve 
Data was analysed using logarithmic analysis as opposed to 4-parameter logistic curve as 
suggested by the manufacturers (R&D Systems). The 4 parameter logistic curve was not 
used as concentration of tumour lysates were not within the range of the standard curve. 
Therefore, no data was obtained for analysis of some of the samples, especially data for 
tumour lysates. The standard curve for logarithmic and 4 parameter logistic curve is 
shown in Figure 41. 
 
 
Figure 41: VEGF ELISA standard curve for logarithmic and 4 parameter logistic analysis 
The graphs above show standard curves generated by (A) logarithmic and (B) 4 parameter logistic 
analysis. The graph for logarithmic was generated using Microsoft excels for mac 2011 version 





































Raw data for absorbance and VEGF concentrations of tumour and internal metastases 
lysates and plasma are shown in Table 13 and Table 14 respectively. The VEGF 
concentrations of lysates are multiplied by the dilution factor of 20. The plasma VEGF 
concentrations are multiplied by the dilution factor of 100. 
 
Table 13: Raw data of absorbance and tumour VEGF concentration by logarithmic and 4 
parameter logistic analysis 
 
Mouse Type Sample No Average 
Absorbance 
[VEGF] in pg/mL 
by logarithmic 
analysis 
[VEGF] in pg/mL 
by 4 parameter 
logistic analysis 
wild type tumour 
lysate 
1 0.296 265.240 426.250 
2 0.447 2087.898 555.875 
3 0.406 1083.622 505.875 
4 0.514 2585.662 0.000 
5 0.373 1427.770 481.925 
6 0.361 444.194 472.575 
7 0.322 630.755 444.700 
8 0.590 7312.437 0.000 
wild type internal 
metastases lysate 
9 0.699 7279.192 0.000 
10 0.624 4025.310 0.000 
11 0.637 5236.021 0.000 
ApoE tumour 
lysate 
12 0.398 805.403 502.375 
13 0.515 4255.034 0.000 
14 0.385 558.243 491.325 
15 0.411 404.076 513.650 
16 0.600 4842.500 0.000 
17 0.505 10567.894 0.000 
ApoE internal 
metastases lysate 
18 0.691 2669.202 0.000 
19 0.521 1728.105 0.000 
20 0.686 11200.547 0.000 
ApoE/ArKO 
tumour lysate 
21 0.414 890.473 516.575 
22 0.710 10176.254 0.000 
23 0.592 4912.404 0.000 
24 0.503 1557.258 0.000 
25 0.571 5898.831 0.000 




Table 14: Raw data of absorbance and plasma VEGF concentration by logarithmic and 4 
parameter logistic analysis 




[VEGF] in pg/mL 
by logarithmic 
analysis 
[VEGF] in pg/mL by 
4 parameter logistic 
analysis 
Plasma from wild 
type mice with 
only primary 
tumour 
35 0.256 3059.511 1584.1 
36 0.384 14387.590 1962.7 
37 0.267 3509.104 1620.2 
39 0.241 2545.031 1532.1 
40 0.262 3300.618 1604.3 
41 0.243 2603.785 1538.8 
42 0.261 3239.116 1599.4 
43 0.074 339.560 0 
44 0.249 2824.341 1562.1 
45 0.258 3141.009 1591.2 
46 0.461 36161.242 2313.4 
Plasma from wild 
type mice with 
internal 
metastases 
34 0.481 46071.427 2532.3 
38 0.393 15932.061 1990.6 
47 0.261 3248.773 1600.1 
Plasma from 
ApoE mice with 
only primary 
tumour 
48 0.212 1811.942 1419.5 
49 0.283 4241.478 1667.8 
50 0.238 2472.997 1523.6 
51 0.221 2015.313 1557.9 
54 0.248 2796.161 1559.3 
55 0.224 2083.010 1469.2 
57 0.189 1367.827 1294.1 
Plasma from 
ApoE mice with 
internal 
metastases 
52 0.208 1718.362 1399 
53 0.312 6046.415 1755.2 
56 0.227 2160.449 1481.3 
Plasma from 
ApoE/ArKO mice 
with only primary 
tumour 
27 0.247 2748.174 1554 
28 0.187 1339.454 1282.7 
29 0.258 3133.686 1590.5 
30 0.292 4713.198 1693.3 
31 0.290 4601.528 1687.5 
32 0.275 3834.623 1624.2 
33 0.191 1402.703 1307.8 





There was no significant difference in the VEGF concentration of plasma from wild type, 
ApoE and ApoE/ArKO mice with only primary tumour burden (Figure 42). Although it 
appeared that the plasma from wild type mice with internal metastases had higher VEGF 
concentration than ApoE mice with internal metastases but the difference was not 
statistically significant (Figure 43).  
 
 
Figure 42: VEGF ELISA for plasma from wild type, ApoE and ApoE/ArKO mice by 4 parameter 
logistic analysis 
The graph shows the VEGF protein expression detected by Mouse ELISA kit in wild type (n=10), 
ApoE (n=7) and ApoE/ArKO (n=8) mice. Plasma of wild type (n=3) and ApoE (n=3) that has internal 
metastasis were also grouped separately. Data were analysed using 1way ANOVA followed by 
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